

EMT, CSCs, and drug resistance: the mechanistic link and

Nature Reviews Clinical Oncology

14, 611-629

DOI: [10.1038/nrclinonc.2017.44](https://doi.org/10.1038/nrclinonc.2017.44)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. <i>Molecular Oncology</i> , 2017, 11, 781-791.	2.1	106
2	Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. <i>Drug Resistance Updates</i> , 2017, 32, 23-46.	6.5	109
3	Neuroblastoma Metastases: Leveraging the Avian Neural Crest. <i>Cancer Cell</i> , 2017, 32, 395-397.	7.7	4
4	Seeing whole-tumour heterogeneity. <i>Nature Biomedical Engineering</i> , 2017, 1, 772-774.	11.6	10
5	Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. <i>Cancer Research</i> , 2017, 77, 6415-6428.	0.4	206
6	Cell plasticity in epithelial homeostasis and tumorigenesis. <i>Nature Cell Biology</i> , 2017, 19, 1133-1141.	4.6	170
7	EMT, inflammation and metastasis. <i>Seminars in Cancer Biology</i> , 2017, 47, 168-169.	4.3	23
8	Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. <i>Biochemical Journal</i> , 2017, 474, 3269-3306.	1.7	53
9	Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 42-51.	2.6	54
10	Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. <i>Cancer Research</i> , 2017, 77, 5194-5206.	0.4	139
11	Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 905-910.	0.9	42
12	A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. <i>Drug Resistance Updates</i> , 2017, 31, 43-51.	6.5	43
13	TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 1337-1349.	1.6	44
14	miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHO/EMT axis. <i>Cell Death and Disease</i> , 2017, 8, e3129-e3129.	2.7	33
15	Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139.	1.8	56
16	HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 1113-1118.	0.8	10
19	Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition. <i>Medical Science Monitor</i> , 2017, 23, 3393-3403.	0.5	69
20	Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance. <i>Critical Reviews in Oncogenesis</i> , 2017, 22, 275-282.	0.2	24

#	ARTICLE	IF	CITATIONS
21	Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer. <i>Cancers</i> , 2017, 9, 104.	1.7	73
22	Glycans as Regulatory Elements of the Insulin/IGF System: Impact in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1921.	1.8	20
23	Drug Resistance Driven by Cancer Stem Cells and Their Niche. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2574.	1.8	376
24	Targeting Metastasis with Snake Toxins: Molecular Mechanisms. <i>Toxins</i> , 2017, 9, 390.	1.5	22
25	Commentary: HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of CD44 during epithelial-mesenchymal transition. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 91.	1.8	2
26	Roles of Integrin $\alpha 6 \beta 4$ Glycosylation in Cancer. <i>Cancers</i> , 2017, 9, 79.	1.7	29
27	Integrins and Exosomes, a Dangerous Liaison in Cancer Progression. <i>Cancers</i> , 2017, 9, 95.	1.7	96
28	Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 101.	1.7	56
29	The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis. <i>Cancers</i> , 2017, 9, 131.	1.7	45
30	Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 295.	1.3	96
31	Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory. <i>Cancers</i> , 2017, 9, 70.	1.7	70
32	Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF- κ B-TNF α -PIK3CA loop. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 164.	3.5	75
33	Management and potentialities of primary cancer cultures in preclinical and translational studies. <i>Journal of Translational Medicine</i> , 2017, 15, 229.	1.8	75
34	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486.	1.1	5
35	Circular RNA profile indicates circular RNA VPK1 is negatively related with breast cancer stem cells. <i>Oncotarget</i> , 2017, 8, 95704-95718.	0.8	55
36	Metastatic ability and the epithelial-mesenchymal transition in induced cancer stem-like hepatoma cells. <i>Cancer Science</i> , 2018, 109, 1101-1109.	1.7	27
37	Immune checkpoint blockade combined with α IL-6 and α TGF β 2 inhibition improves the therapeutic outcome of mRNA-based immunotherapy. <i>International Journal of Cancer</i> , 2018, 143, 686-698.	2.3	31
38	Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells. <i>Pathology International</i> , 2018, 68, 214-223.	0.6	24

#	ARTICLE	IF	CITATIONS
39	Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 341-358.	12.8	248
40	Characterising the phenotypic evolution of circulating tumour cells during treatment. <i>Nature Communications</i> , 2018, 9, 1482.	5.8	86
41	Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. <i>Stem Cells Translational Medicine</i> , 2018, 7, 495-501.	1.6	59
42	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
43	Single-cell RNA-seq analysis unveils a prevalent epithelial/mesenchymal hybrid state during mouse organogenesis. <i>Genome Biology</i> , 2018, 19, 31.	3.8	153
44	Cancer development and therapy resistance: spotlights on the dark side of the genome. , 2018, 189, 22-30.		21
45	In vivo optical imaging of cancer cell function and tumor microenvironment. <i>Cancer Science</i> , 2018, 109, 912-918.	1.7	51
46	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1433982.	2.1	38
47	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. <i>Cell Systems</i> , 2018, 6, 343-354.e5.	2.9	40
48	Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. <i>Cell Reports</i> , 2018, 22, 1875-1888.	2.9	83
49	Epithelial Mesenchymal Transition in Tumor Metastasis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 395-412.	9.6	896
50	MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. <i>Oncogene</i> , 2018, 37, 2079-2088.	2.6	50
51	Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers. <i>Journal of Cellular Physiology</i> , 2018, 233, 6359-6369.	2.0	21
52	High Expression of Prospero-Related Homeobox-1 (PROX1) Is Associated With Poor Prognosis in Patients With Salivary Adenoid Cystic Carcinoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018, 76, 1440-1446.	0.5	2
53	Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells. <i>Cancer Research</i> , 2018, 78, 1604-1618.	0.4	83
54	Histone Variant MacroH2A1 Plays an Isoform-Specific Role in Suppressing Epithelial-Mesenchymal Transition. <i>Scientific Reports</i> , 2018, 8, 841.	1.6	24
55	Biomarker discovery for renal cancer stem cells. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 3-18.	1.3	67
56	PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling. <i>Cell Death and Disease</i> , 2018, 9, 192.	2.7	33

#	ARTICLE	IF	CITATIONS
57	Paeoniflorin Inhibits Migration and Invasion of Human Glioblastoma Cells via Suppression Transforming Growth Factor β 2-Induced Epithelial-Mesenchymal Transition. <i>Neurochemical Research</i> , 2018, 43, 760-774.	1.6	41
58	LTBP3 promotes early metastatic events during cancer cell dissemination. <i>Oncogene</i> , 2018, 37, 1815-1829.	2.6	17
59	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	5.0	4,036
60	CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. <i>Cancer Research</i> , 2018, 78, 1657-1671.	0.4	97
61	Pleiotropic Roles for ZEB1 in Cancer. <i>Cancer Research</i> , 2018, 78, 30-35.	0.4	234
64	Targeting melanoma stem cells with the Vitamin E derivative γ -tocotrienol. <i>Scientific Reports</i> , 2018, 8, 587.	1.6	46
65	Laser Microdissection of Cellular Compartments for Expression Analyses in Cancer Models. <i>Methods in Molecular Biology</i> , 2018, 1725, 143-153.	0.4	0
66	Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. <i>Neoplasia</i> , 2018, 20, 197-206.	2.3	34
67	Chemotherapy-induced metastasis: mechanisms and translational opportunities. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 269-284.	1.7	106
68	NRF2 and the Hallmarks of Cancer. <i>Cancer Cell</i> , 2018, 34, 21-43.	7.7	1,016
69	Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer. <i>Molecular Cancer</i> , 2018, 17, 42.	7.9	16
70	Role of the HGF/c-MET tyrosine kinase inhibitors in metastatic melanoma. <i>Molecular Cancer</i> , 2018, 17, 26.	7.9	47
71	Bioluminescence Imaging for Monitoring miR-200c Expression in Breast Cancer Cells and its Effects on Epithelial-Mesenchymal Transition Progress in Living Animals. <i>Molecular Imaging and Biology</i> , 2018, 20, 761-770.	1.3	9
72	Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. <i>Cell Death and Differentiation</i> , 2018, 25, 1259-1275.	5.0	59
73	Secreted molecules inducing epithelial-to-mesenchymal transition in cancer development. <i>Seminars in Cell and Developmental Biology</i> , 2018, 78, 62-72.	2.3	20
74	Autocrine mechanisms of cancer chemoresistance. <i>Seminars in Cell and Developmental Biology</i> , 2018, 78, 3-12.	2.3	24
75	Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis. <i>Developmental Dynamics</i> , 2018, 247, 405-431.	0.8	36
76	High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. <i>Laboratory Investigation</i> , 2018, 98, 95-105.	1.7	41

#	ARTICLE	IF	CITATIONS
77	RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). <i>Endocrine-Related Cancer</i> , 2018, 25, T105-T119.	1.6	19
78	Mesenchymal stromal cell engagement in cancer cell epithelial to mesenchymal transition. <i>Developmental Dynamics</i> , 2018, 247, 359-367.	0.8	9
79	Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling. <i>Advanced Healthcare Materials</i> , 2018, 7, e1700980.	3.9	96
80	Lineage Plasticity in Cancer Progression and Treatment. <i>Annual Review of Cancer Biology</i> , 2018, 2, 271-289.	2.3	66
81	Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. <i>Oncotarget</i> , 2018, 9, 8985-8998.	0.8	6
82	PNUTS at the crossroads of tumorigenesis and metastasis formation. <i>Journal of Thoracic Disease</i> , 2018, 10, 560-563.	0.6	5
83	Therapeutic potential of tumor associated macrophages. <i>Annals of Blood</i> , 0, 3, 27-27.	0.4	0
84	Epithelial-mesenchymal transition-induced metastasis could be a bait for natural killer cells. <i>Journal of Thoracic Disease</i> , 2018, 10, S3143-S3146.	0.6	4
85	Epithelial-Mesenchymal Transition. , 2018, , .		0
86	Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy. <i>Advanced Functional Materials</i> , 2018, 28, 1804229.	7.8	43
87	An Optically Induced Dielectrophoresis (ODEP)-Based Microfluidic System for the Isolation of High-Purity CD45 ^{neg} /EpCAM ^{neg} Cells from the Blood Samples of Cancer Patients Demonstration and Initial Exploration of the Clinical Significance of These Cells. <i>Micromachines</i> , 2018, 9, 563.	1.4	35
88	KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. <i>Cancer Cell</i> , 2018, 34, 939-953.e9.	7.7	170
89	Targeted Nanomedicine to Treat Bone Metastasis. <i>Pharmaceutics</i> , 2018, 10, 205.	2.0	38
90	MicroRNA-301a targets WNT1 to suppress cell proliferation and migration and enhance radiosensitivity in esophageal cancer cells. <i>Oncology Reports</i> , 2018, 41, 599-607.	1.2	23
91	Cancer stem cells in progression of colorectal cancer. <i>Oncotarget</i> , 2018, 9, 33403-33415.	0.8	179
92	Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review). <i>International Journal of Oncology</i> , 2018, 54, 420-430.	1.4	17
93	Glutathione peroxidase 4 maintains a stemness phenotype, oxidative homeostasis and regulates biological processes in Panc-1 cancer stem-like cells. <i>Oncology Reports</i> , 2018, 41, 1264-1274.	1.2	22
94	Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells. <i>Stem Cells International</i> , 2018, 2018, 1-12.	1.2	17

#	ARTICLE	IF	CITATIONS
95	Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells. <i>Cancer Research</i> , 2018, 78, 6713-6716.	0.4	22
96	Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance. <i>Cancers</i> , 2018, 10, 482.	1.7	54
97	Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. <i>Frontiers in Oncology</i> , 2018, 8, 386.	1.3	209
98	Epigenetically distinct sister chromatids and asymmetric generation of tumor initiating cells. <i>Cell Cycle</i> , 2018, 17, 2221-2229.	1.3	1
99	Apthous ulcer drug inhibits prostate tumor metastasis by targeting IKK ϵ /TBK1/NF- κ B signaling. <i>Theranostics</i> , 2018, 8, 4633-4648.	4.6	27
100	Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer. <i>Cancer Science</i> , 2018, 109, 3461-3470.	1.7	4
101	Novel silk fibroin nanoparticles incorporated silk fibroin hydrogel for inhibition of cancer stem cells and tumor growth. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 5405-5418.	3.3	39
102	Obesity-Activated Adipose-Derived Stromal Cells Promote Breast Cancer Growth and Invasion. <i>Neoplasia</i> , 2018, 20, 1161-1174.	2.3	30
103	Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells. <i>Scientific Reports</i> , 2018, 8, 15737.	1.6	43
104	Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells. <i>Molecules</i> , 2018, 23, 2690.	1.7	7
105	YAP regulates ALDH1A1 expression and stem cell property of bladder cancer cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6657-6663.	1.0	20
106	Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 105, 84-93.	1.2	8
107	Blocking Endogenous H ₂ S Signaling Attenuated Radiation-Induced Long-Term Metastasis of Residual HepG2 Cells through Inhibition of EMT. <i>Radiation Research</i> , 2018, 190, 374.	0.7	17
108	GLI3 knockdown decreases stemness, cell proliferation and invasion in oral squamous cell carcinoma. <i>International Journal of Oncology</i> , 2018, 53, 2458-2472.	1.4	19
109	Glucosamine decreases the stemness of human ALDH+ breast cancer stem cells by inactivating STAT3. <i>Oncology Letters</i> , 2018, 16, 4737-4744.	0.8	14
110	Malignant Transformation and Spine Metastasis of an Intracranial Grade I Meningioma: In Situ Immunofluorescence Analysis of Cancer Stem Cells Case Report and Literature Review. <i>World Neurosurgery</i> , 2018, 120, 274-289.	0.7	5
111	Cells with stemness features are generated from in vitro transformed human fibroblasts. <i>Scientific Reports</i> , 2018, 8, 13838.	1.6	8
112	The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 563-599.	1.7	25

#	ARTICLE	IF	CITATIONS
113	Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems. <i>Journal of Controlled Release</i> , 2018, 288, 62-83.	4.8	101
114	<i>Crebbp</i> Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1422-1437.	7.7	126
115	Simultaneous Fluorescence Visualization of Epithelial-to-Mesenchymal Transition and Apoptosis Processes in Tumor Cells for Evaluating the Impact of Epithelial-to-Mesenchymal Transition on Drug Efficacy. <i>Analytical Chemistry</i> , 2018, 90, 10951-10957.	3.2	28
116	Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. <i>Cell Reports</i> , 2018, 23, 2095-2106.	2.9	37
117	Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 1693-1708.	4.2	31
118	Ras Post-transcriptionally Enhances a Pre-malignantly Primed EMT to Promote Invasion. <i>Science</i> , 2018, 4, 97-108.	1.9	7
119	Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2018, 78, 4150-4162.	0.4	245
120	The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. <i>Archives of Toxicology</i> , 2018, 92, 2227-2243.	1.9	57
121	Microenvironmental Cues Determine Tumor Cell Susceptibility to Neutrophil Cytotoxicity. <i>Cancer Research</i> , 2018, 78, 5050-5059.	0.4	29
122	Reciprocal expression of Slug and Snail in human oral cancer cells. <i>PLoS ONE</i> , 2018, 13, e0199442.	1.1	52
123	Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells. <i>Nature Communications</i> , 2018, 9, 2424.	5.8	18
124	Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. <i>Journal of Cellular Physiology</i> , 2018, 233, 9136-9144.	2.0	80
125	The Role of Actin Dynamics and Actin-Binding Proteins Expression in Epithelial-to-Mesenchymal Transition and Its Association with Cancer Progression and Evaluation of Possible Therapeutic Targets. <i>BioMed Research International</i> , 2018, 2018, 1-13.	0.9	101
126	Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. <i>PLoS ONE</i> , 2018, 13, e0199361.	1.1	9
127	A Meta-Analysis Characterizing Stem-Like Gene Expression in the Suprachiasmatic Nucleus and Its Circadian Clock. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	9
128	SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells. <i>Biochemical Pharmacology</i> , 2018, 156, 43-51.	2.0	7
129	B7H3 As a Promoter of Metastasis and Promising Therapeutic Target. <i>Frontiers in Oncology</i> , 2018, 8, 264.	1.3	86
130	Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. <i>Frontiers of Medicine</i> , 2018, 12, 361-373.	1.5	467

#	ARTICLE	IF	CITATIONS
131	EMT-related long non-coding RNA in hepatocellular carcinoma: A study with TCGA database. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1530-1536.	1.0	26
132	P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. <i>Journal of Controlled Release</i> , 2018, 286, 289-300.	4.8	18
133	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF β 1 Axis. <i>Clinical Cancer Research</i> , 2018, 24, 6078-6097.	3.2	43
134	OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma. <i>Theranostics</i> , 2018, 8, 2202-2216.	4.6	50
135	p53-Dependent and -Independent Epithelial Integrity: Beyond miRNAs and Metabolic Fluctuations. <i>Cancers</i> , 2018, 10, 162.	1.7	15
136	Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States. <i>Cells</i> , 2018, 7, 21.	1.8	167
137	Epithelial Mesenchymal Transition in Embryonic Development, Tissue Repair and Cancer: A Comprehensive Overview. <i>Journal of Clinical Medicine</i> , 2018, 7, 1.	1.0	238
138	Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer. <i>Molecules</i> , 2018, 23, 727.	1.7	31
139	miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 523-531.	2.5	34
140	Epithelialâ€mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?. <i>Oncogene</i> , 2018, 37, 6195-6211.	2.6	131
141	Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. <i>Nature Communications</i> , 2018, 9, 2682.	5.8	62
142	Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 353-367.	2.1	64
143	Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1267-1272.	1.0	51
144	Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 10.	1.8	114
145	Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 44.	1.8	38
146	Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1509-1521.	1.2	25
147	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. <i>Npj Breast Cancer</i> , 2018, 4, 9.	2.3	32
148	Involvement of partial EMT in cancer progression. <i>Journal of Biochemistry</i> , 2018, 164, 257-264.	0.9	370

#	ARTICLE	IF	CITATIONS
149	Time-course analysis of microRNA-induced mesenchymal-to-epithelial transition underscores the complexity of the underlying molecular processes. <i>Cancer Letters</i> , 2018, 428, 184-191.	3.2	7
150	A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF7 breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2018, 42, 1987-1997.	1.8	7
151	Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis. <i>Journal of Pharmacological Sciences</i> , 2018, 137, 305-312.	1.1	58
152	Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy. <i>Nature Communications</i> , 2018, 9, 3430.	5.8	44
153	Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor. <i>Molecular Cancer Research</i> , 2018, 16, 1952-1964.	1.5	48
154	A comprehensive look at the role of hyperlipidemia in promoting colorectal cancer liver metastasis. <i>Journal of Cancer</i> , 2018, 9, 2981-2986.	1.2	15
155	Cancer cell plasticity: Impact on tumor progression and therapy response. <i>Seminars in Cancer Biology</i> , 2018, 53, 48-58.	4.3	148
156	Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cells. <i>Cancer Medicine</i> , 2018, 7, 3548-3560.	1.3	21
157	Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization. <i>American Journal of Reproductive Immunology</i> , 2018, 80, e12996.	1.2	13
158	Arginine methylation of SMAD7 by PRMT1 in TGF- β -induced epithelial-mesenchymal transition and epithelial stem-cell generation. <i>Journal of Biological Chemistry</i> , 2018, 293, 13059-13072.	1.6	56
159	HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma. <i>Cancer Letters</i> , 2018, 432, 121-131.	3.2	13
160	Mitostemness. <i>Cell Cycle</i> , 2018, 17, 918-926.	1.3	15
161	The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 285-308.	1.7	47
162	Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. <i>PLoS ONE</i> , 2018, 13, e0191109.	1.1	100
163	An SPR based immunoassay for the sensitive detection of the soluble epithelial marker E-cadherin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1963-1971.	1.7	15
164	Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4900-4912.	3.2	24
165	EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 1136.	1.7	88
166	Transition from mesenchymal to bleb-based motility is predominantly exhibited by CD133-positive subpopulation of fibrosarcoma cells. <i>Biology of the Cell</i> , 2019, 111, 245-261.	0.7	11

#	ARTICLE	IF	CITATIONS
167	miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt β -catenin pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 358.	3.5	51
168	The Tumor Microenvironment of Pediatric Sarcoma: Mesenchymal Mechanisms Regulating Cell Migration and Metastasis. <i>Current Oncology Reports</i> , 2019, 21, 90.	1.8	32
169	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	1.2	27
170	PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. <i>Cancers</i> , 2019, 11, 1076.	1.7	108
171	Sulforaphane inhibits epithelial \rightarrow mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells. <i>Journal of Nutritional Biochemistry</i> , 2019, 72, 108219.	1.9	19
172	Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. <i>Scientific Reports</i> , 2019, 9, 10845.	1.6	18
173	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. <i>BMC Cancer</i> , 2019, 19, 760.	1.1	78
174	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 1372-1387.	7.7	158
175	Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer. <i>Neoplasia</i> , 2019, 21, 963-973.	2.3	2
176	<p>Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 67-80.	1.3	6
177	Identification and Targeting of Stem Cell-Activated Pathways in Cancer Therapy. <i>Stem Cells International</i> , 2019, 2019, 1-2.	1.2	8
178	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
179	Oxaliplatin reverses the GLP β -mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling. <i>Oncology Letters</i> , 2019, 18, 1989-1998.	0.8	6
180	Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. <i>Cancers</i> , 2019, 11, 934.	1.7	45
181	ZnAs@SiO ₂ nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. <i>Theranostics</i> , 2019, 9, 4391-4408.	4.6	52
182	The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression. <i>Science Advances</i> , 2019, 5, eaaw6710.	4.7	35
183	Immunohistochemical Features of Epithelial-Mesenchymal Transition in Feline Oral Squamous Cell Carcinoma. <i>Veterinary Pathology</i> , 2019, 56, 826-839.	0.8	18
184	The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 1028.	1.7	54

#	ARTICLE	IF	CITATIONS
185	Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 1058.	1.7	32
186	Boosting the Ferroptotic Antitumor Efficacy via Site-Specific Amplification of Tailored Lipid Peroxidation. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 29655-29666.	4.0	68
187	Development and validation of a primate model for liver fibrosis. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 100, 106600.	0.3	2
188	New Insights into the Role of Polybromo-1 in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2852.	1.8	13
189	Fibroblasts in cancer: Defining target structures for therapeutic intervention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 111-121.	3.3	14
190	Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices. <i>Frontiers in Oncology</i> , 2019, 9, 613.	1.3	130
191	The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?. <i>Cancers</i> , 2019, 11, 902.	1.7	21
192	Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine. <i>Cell Stress</i> , 2019, 3, 267-279.	1.4	45
193	XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109519.	2.5	20
194	LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells. <i>Oncogenesis</i> , 2019, 8, 60.	2.1	59
195	The Histone Demethylase LSD1/DM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. <i>Cancers</i> , 2019, 11, 1585.	1.7	47
196	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019, 16, 655-673.	1.9	24
197	Triggered All-Active Metal Organic Framework: Ferroptosis Machinery Contributes to the Apoptotic Photodynamic Antitumor Therapy. <i>Nano Letters</i> , 2019, 19, 7866-7876.	4.5	228
198	Epithelial-mesenchymal plasticityâ€”engaging stemness in an interplay of phenotypes. <i>Stem Cell Investigation</i> , 2019, 6, 25-25.	1.3	27
199	<p>Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8161-8177.	1.0	2
200	Novel discoveries targeting gemcitabineâ€”based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. <i>Cancer Medicine</i> , 2019, 8, 6403-6413.	1.3	17
201	Redox-Mediated Mechanism of Chemoresistance in Cancer Cells. <i>Antioxidants</i> , 2019, 8, 471.	2.2	100
202	Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	2

#	ARTICLE	IF	CITATIONS
203	Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. <i>Theranostics</i> , 2019, 9, 7122-7139.	4.6	38
204	Epigenetic heterogeneity in cancer. <i>Biomarker Research</i> , 2019, 7, 23.	2.8	145
205	Controversies around epithelialâ€mesenchymal plasticity in cancer metastasis. <i>Nature Reviews Cancer</i> , 2019, 19, 716-732.	12.8	294
206	Addiction of mesenchymal phenotypes on the FGF/FGFR axis in oral squamous cell carcinoma cells. <i>PLoS ONE</i> , 2019, 14, e0217451.	1.1	12
207	Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. <i>Cancers</i> , 2019, 11, 1745.	1.7	6
208	EBV-miR-BART7-3p Imposes Stemness in Nasopharyngeal Carcinoma Cells by Suppressing SMAD7. <i>Frontiers in Genetics</i> , 2019, 10, 939.	1.1	27
209	EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 1044.	1.3	146
210	PKC± Modulates Epithelial-to-Mesenchymal Transition and Invasiveness of Breast Cancer Cells Through ZEB1. <i>Frontiers in Oncology</i> , 2019, 9, 1323.	1.3	26
211	Role of ACTN4 in Tumorigenesis, Metastasis, and EMT. <i>Cells</i> , 2019, 8, 1427.	1.8	43
212	<p>LOXL 2 Promotes The Epithelialâ€Mesenchymal Transition And Malignant Progression Of Cervical Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8947-8954.	1.0	14
213	Eâ€cadherinâ€Fc chimera protein matrix enhances cancer stemâ€like properties and induces mesenchymal features in colon cancer cells. <i>Cancer Science</i> , 2019, 110, 3520-3532.	1.7	15
214	A genomeâ€wide <scp>RNA</scp> i screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019, 11, e9930.	3.3	27
215	Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS). <i>Biomaterials</i> , 2019, 224, 119489.	5.7	21
216	The role of liver microenvironment in hepatic metastasis. <i>Clinical and Translational Medicine</i> , 2019, 8, 21.	1.7	39
217	ARF6 and AMAP1 are major targets of <i>KRAS</i> and <i>TP53</i> mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17450-17459.	3.3	96
218	Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis. <i>Cancers</i> , 2019, 11, 1274.	1.7	14
219	Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. <i>Biomaterials</i> , 2019, 223, 119486.	5.7	159
220	Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer. <i>Oncogenesis</i> , 2019, 8, 50.	2.1	41

#	ARTICLE	IF	CITATIONS
221	Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2433-2444.	1.2	12
222	Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. <i>Theranostics</i> , 2019, 9, 6209-6223.	4.6	115
223	Control of nucleolar stress and translational reprogramming by lncRNAs. <i>Cell Stress</i> , 2019, 3, 19-26.	1.4	20
224	Functional roles of circular RNAs during epithelial-to-mesenchymal transition. <i>Molecular Cancer</i> , 2019, 18, 138.	7.9	79
226	OCT4B1 Promoted EMT and Regulated the Self-Renewal of CSCs in CRC: Effects Associated with the Balance of miR-8064/PLK1. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 7-20.	2.0	13
227	Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. <i>Cell Communication and Signaling</i> , 2019, 17, 121.	2.7	68
228	MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine. <i>Cancer Cell International</i> , 2019, 19, 232.	1.8	4
229	Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <i>BRAF</i> V600-Mutant Melanoma Patient-Derived Xenografts. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2421-2432.	1.9	2
230	Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1744-1754.	1.9	49
231	CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs). <i>Cells</i> , 2019, 8, 1145.	1.8	92
232	Pathological transition as the arising mechanism for drug resistance in lung cancer. <i>Cancer Communications</i> , 2019, 39, 1-13.	3.7	25
233	Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance. <i>Frontiers in Oncology</i> , 2019, 9, 1003.	1.3	42
234	Cancer Stem Cells Targeting; the Lessons from the Interaction of the Immune System, the Cancer Stem Cells and the Tumor Niche. <i>International Reviews of Immunology</i> , 2019, 38, 267-283.	1.5	12
235	Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1488.	1.7	7
236	Investigating epithelial-to-mesenchymal transition with integrated computational and experimental approaches. <i>Physical Biology</i> , 2019, 16, 031001.	0.8	26
237	Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 105.	1.7	26
238	Therapeutic Potential of a Novel β 3 Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type. <i>Cancers</i> , 2019, 11, 139.	1.7	29
239	PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition. <i>Molecular Medicine Reports</i> , 2019, 19, 2173-2179.	1.1	8

#	ARTICLE	IF	CITATIONS
240	Application of the D492 Cell Lines to Explore Breast Morphogenesis, EMT and Cancer Progression in 3D Culture. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 139-147.	1.0	20
241	S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 39-50.	1.1	55
242	Sonic hedgehog pathway activation regulates cervical cancer stem cell characteristics during epithelial to mesenchymal transition. <i>Journal of Cellular Physiology</i> , 2019, 234, 15726-15741.	2.0	26
243	Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers. <i>Experimental Hematology</i> , 2019, 71, 61-67.	0.2	6
244	<p>Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β2/Smad2/3 signaling pathway</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3893-3903.	1.0	53
245	Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response. <i>Journal of Clinical Medicine</i> , 2019, 8, 725.	1.0	63
246	Hyaluronic acid hydrogels with defined crosslink density for the efficient enrichment of breast cancer stem cells. <i>Acta Biomaterialia</i> , 2019, 94, 320-329.	4.1	21
247	Estrogen receptor ±NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer. <i>Cell Communication and Signaling</i> , 2019, 17, 50.	2.7	24
248	Stem Cells Heterogeneity in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	2
249	Absent in melanoma 2 suppresses epithelialâ€mesenchymal transition via Akt and inflammasome pathways in human colorectal cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 17744-17756.	1.2	8
250	The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. <i>Cancers</i> , 2019, 11, 838.	1.7	160
251	Regulation of TEAD Transcription Factors in Cancer Biology. <i>Cells</i> , 2019, 8, 600.	1.8	159
252	KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stemâ€Like Cells and Promotes Metastasis. <i>Molecular Cancer Research</i> , 2019, 17, 1945-1957.	1.5	31
253	Cancer stem cell fate determination: a nuclear phenomenon. <i>Nucleus (India)</i> , 2019, 62, 109-118.	0.9	1
254	Unmasking senescence: context-dependent effects of SASP in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 439-453.	12.8	465
255	Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1219-1227.	2.8	41
256	Endothelial cell clonal expansion in the development of cerebral cavernous malformations. <i>Nature Communications</i> , 2019, 10, 2761.	5.8	87
257	Cancer Stem Cells and Radioresistance: DNA Repair and Beyond. <i>Cancers</i> , 2019, 11, 862.	1.7	196

#	ARTICLE	IF	CITATIONS
258	miR-338-3p inhibits A549 lung cancer cell proliferation and invasion by targeting AKT and β -catenin signaling pathways. <i>Molecular Medicine Reports</i> , 2019, 20, 33-40.	1.1	10
259	FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies. <i>Bioscience Reports</i> , 2019, 39, .	1.1	24
260	The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients. <i>Cancers</i> , 2019, 11, 783.	1.7	14
261	Heterogeneity and Plasticity of Breast Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 83-103.	0.8	42
262	Controlling distinct signaling states in cultured cancer cells provides a new platform for drug discovery. <i>FASEB Journal</i> , 2019, 33, 9235-9249.	0.2	7
263	Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. <i>Cancers</i> , 2019, 11, 732.	1.7	134
264	Preserving Genome Integrity during the Early Embryonic DNA Replication Cycles. <i>Genes</i> , 2019, 10, 398.	1.0	34
265	Epithelial-Mesenchymal Plasticity in Organotropism Metastasis and Tumor Immune Escape. <i>Journal of Clinical Medicine</i> , 2019, 8, 747.	1.0	17
266	Extrachromosomal circular DNAs: an extra piece of evidence to depict tumor heterogeneity. <i>Future Science OA</i> , 2019, 5, FSO390.	0.9	22
267	miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells. <i>Gene</i> , 2019, 710, 103-113.	1.0	37
268	Dynamics of Minimal Residual Disease in Neuroblastoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 455.	1.3	35
269	Hypoxia and Cancer Metastasis. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	5
270	Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1136, 43-55.	0.8	49
271	Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model. <i>Cell Death and Disease</i> , 2019, 10, 467.	2.7	28
272	Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines. <i>Molecular and Cellular Biochemistry</i> , 2019, 459, 35-47.	1.4	19
273	Dual Delivery of HNF4 α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 19808-19818.	4.0	40
274	Landscape perspectives of tumor, EMT, and development. <i>Physical Biology</i> , 2019, 16, 051003.	0.8	8
275	Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. <i>Nature Communications</i> , 2019, 10, 2110.	5.8	139

#	ARTICLE	IF	CITATIONS
276	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. <i>Cancer Discovery</i> , 2019, 9, 962-979.	7.7	58
277	Contribution of Epithelial Plasticity to Therapy Resistance. <i>Journal of Clinical Medicine</i> , 2019, 8, 676.	1.0	42
278	Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications. <i>Cancers</i> , 2019, 11, 616.	1.7	73
279	Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2256.	1.8	97
280	Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 170.	3.5	71
281	Single-cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer. <i>Oncology Reports</i> , 2019, 41, 3201-3208.	1.2	10
282	Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. <i>Molecular Cancer</i> , 2019, 18, 90.	7.9	282
283	UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC. <i>Theranostics</i> , 2019, 9, 2036-2055.	4.6	32
284	EMT and Cancer: More Than Meets the Eye. <i>Developmental Cell</i> , 2019, 49, 313-316.	3.1	218
285	Musashi2 and related stem cell proteins in the mouse suprachiasmatic nucleus and their potential role in circadian rhythms. <i>International Journal of Developmental Neuroscience</i> , 2019, 75, 44-58.	0.7	3
286	A Fluorescence-Activated Single-Droplet Dispenser for High Accuracy Single-Droplet and Single-Cell Sorting and Dispensing. <i>Analytical Chemistry</i> , 2019, 91, 6815-6819.	3.2	26
287	Cellular Plasticity in Cancer. <i>Cancer Discovery</i> , 2019, 9, 837-851.	7.7	309
288	Targeting stem cells in the realm of drug-resistant breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 115-135.	1.0	33
289	GSK3 β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 37.	2.2	102
290	MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , 2019, 79, 2031-2041.	0.4	28
291	Deciphering the Dynamics of Epithelial-Mesenchymal Transition and Cancer Stem Cells in Tumor Progression. <i>Current Stem Cell Reports</i> , 2019, 5, 11-21.	0.7	27
292	TARGET-seq Takes Aim at Cancer Evolution through Multi-omics Single-Cell Genotyping and Transcriptomics. <i>Molecular Cell</i> , 2019, 73, 1092-1094.	4.5	3
293	SATB2-AS1 Suppresses Colorectal Carcinoma Aggressiveness by Inhibiting SATB2-Dependent Snail Transcription and Epithelial-Mesenchymal Transition. <i>Cancer Research</i> , 2019, 79, 3542-3556.	0.4	75

#	ARTICLE	IF	CITATIONS
294	CXCL12/CXCR4 pathway orchestrates CSC-like properties by CAF recruited tumor associated macrophage in OSCC. <i>Experimental Cell Research</i> , 2019, 378, 131-138.	1.2	119
295	Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 484-499.	1.5	11
296	MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 126.	3.5	41
297	Re-establishing Apoptosis Competence in Bone Associated Cancers via Communicative Reprogramming Induced Through Notch Signaling Inhibition. <i>Frontiers in Pharmacology</i> , 2019, 10, 145.	1.6	10
298	KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program. <i>Cancer Letters</i> , 2019, 454, 78-89.	3.2	41
299	Conventional and Novel Diagnostic Biomarkers and Approaches for Detection of Nasopharyngeal Carcinoma. , 2019, , 129-153.		1
300	Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy. <i>Cell Death and Disease</i> , 2019, 10, 285.	2.7	59
302	ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1427-1436.	1.2	10
303	Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1 α axis in esophageal squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2019, 109, 104239.	0.9	13
304	Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of Photodynamic Therapy. <i>Scientific Reports</i> , 2019, 9, 4835.	1.6	17
305	Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. <i>Cancer Cell</i> , 2019, 35, 618-632.e6.	7.7	119
306	<p>Paradoxical effects of cellular senescence-inhibited gene involved in hepatocellular carcinoma migration and proliferation by ERK pathway and mesenchymal-like markers</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2035-2046.	1.0	3
307	The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. <i>Cancers</i> , 2019, 11, 434.	1.7	74
308	Activation of IGF/IGF-IR signaling pathway fails to induce epithelial-mesenchymal transition in pancreatic cancer cells. <i>Pancreatology</i> , 2019, 19, 390-396.	0.5	20
309	The emerging roles of macrophages in cancer metastasis and response to chemotherapy. <i>Journal of Leukocyte Biology</i> , 2019, 106, 259-274.	1.5	80
310	Nucleus-targeted nano delivery system eradicates cancer stem cells by combined thermotherapy and hypoxia-activated chemotherapy. <i>Biomaterials</i> , 2019, 200, 1-14.	5.7	80
311	The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity. <i>PLoS ONE</i> , 2019, 14, e0208287.	1.1	23
312	Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. <i>Cell Death and Differentiation</i> , 2019, 26, 2223-2236.	5.0	39

#	ARTICLE	IF	CITATIONS
313	A Reporter System Evaluates Tumorigenesis, Metastasis, β -catenin/MMP Regulation, and Druggability. <i>Tissue Engineering - Part A</i> , 2019, 25, 1413-1425.	1.6	19
314	Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 57.	3.5	43
315	Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 109, 90-104.	1.2	62
316	Chronic TGF- β 2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. <i>Science Signaling</i> , 2019, 12, .	1.6	166
317	Epithelial-mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells. <i>Molecular Medicine Reports</i> , 2019, 19, 1501-1508.	1.1	8
318	Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential. <i>Advances in Biological Regulation</i> , 2019, 72, 63-77.	1.4	19
319	ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7. <i>Cell Death and Disease</i> , 2019, 10, 33.	2.7	32
320	MEK5/ERK5 activation regulates colon cancer stem-like cell properties. <i>Cell Death Discovery</i> , 2019, 5, 68.	2.0	34
321	New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 377-387.	2.6	45
322	Kinetic Aspects of the Interplay of Cancer and the Immune System. <i>Biophysical Reviews and Letters</i> , 2019, 14, 101-114.	0.9	3
323	Precision medicine for human cancers with Notch signaling dysregulation (Review). <i>International Journal of Molecular Medicine</i> , 2020, 45, 279-297.	1.8	105
324	Single-cell proteolytic activity measurement using microfluidics for rare cell populations. <i>Methods in Enzymology</i> , 2019, 628, 129-143.	0.4	0
325	Targeting Breast Cancer Stem Cells: A Methodological Perspective. <i>Current Stem Cell Research and Therapy</i> , 2019, 14, 389-397.	0.6	6
326	<p><miR-520b Promotes Breast Cancer Stemness Through Hippo/YAP Signaling Pathway</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11691-11700.	1.0	22
327	The Role of MicroRNAs upon Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. <i>Cells</i> , 2019, 8, 1461.	1.8	13
328	The Effect of Vascular Endothelial Growth Factor on Bone Marrow Mesenchymal Stem Cell Engraftment in Rat Fibrotic Liver upon Transplantation. <i>Stem Cells International</i> , 2019, 2019, 1-13.	1.2	7
329	PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 906-919.	1.9	18
330	Ovarian Cancer-Why Lipids Matter. <i>Cancers</i> , 2019, 11, 1870.	1.7	57

#	ARTICLE	IF	CITATIONS
331	Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 48.	7.1	49
332	Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. <i>Cancer Cell International</i> , 2019, 19, 317.	1.8	19
333	ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1. <i>Cancers</i> , 2019, 11, 1881.	1.7	17
334	miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. <i>Cell Death and Disease</i> , 2019, 10, 922.	2.7	57
335	CD47-SIRP α Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma. <i>Cells</i> , 2019, 8, 1658.	1.8	53
336	Anticancer Properties of Curcumin and Interactions With the Circadian Timing System. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541988915.	0.8	6
337	TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 60.	7.1	40
338	Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development. <i>Cancers</i> , 2019, 11, 1989.	1.7	18
339	The pro-tumorigenic host response to cancer therapies. <i>Nature Reviews Cancer</i> , 2019, 19, 667-685.	12.8	135
340	Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab. <i>Medicine (United States)</i> , 2019, 98, e16937.	0.4	3
344	The molecular limitations of biomarker research in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 837-848.	1.2	31
345	Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β 3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. <i>Theranostics</i> , 2019, 9, 265-278.	4.6	141
346	Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. <i>Cancer Letters</i> , 2019, 444, 82-93.	3.2	35
347	Testing the gene expression classification of the EMT spectrum. <i>Physical Biology</i> , 2019, 16, 025002.	0.8	35
348	Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. <i>Biomaterials</i> , 2019, 192, 590-600.	5.7	61
349	Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 107, 116-127.	1.2	22
350	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019, 21, 185-196.	2.3	38
351	Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 680-692.	1.9	52

#	ARTICLE	IF	CITATIONS
352	The roles of ZEB1 in tumorigenic progression and epigenetic modifications. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 400-408.	2.5	106
353	Autophagy, cancer stem cells and drug resistance. <i>Journal of Pathology</i> , 2019, 247, 708-718.	2.1	268
354	Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrineâ€“Paracrine Loop. <i>Clinical Cancer Research</i> , 2019, 25, 1957-1969.	3.2	59
355	Fractionated radiotherapy might induce epithelialâ€“mesenchymal transition and radioresistance in a cellular context manner. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8601-8610.	1.2	19
356	Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 437-447.	1.9	133
357	BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits. <i>Redox Biology</i> , 2019, 20, 427-441.	3.9	45
358	New insights into the mechanisms of epithelialâ€“mesenchymal transition and implications for cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 69-84.	16.1	2,319
359	Blockade of TGF- β 2 signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. <i>Oncolmmunology</i> , 2019, 8, e1539613.	2.1	33
361	PPP3CB Inhibits Migration of G401 Cells via Regulating Epithelial-to-Mesenchymal Transition and Promotes G401 Cells Growth. <i>International Journal of Molecular Sciences</i> , 2019, 20, 275.	1.8	6
362	Metal carcinogen exposure induces cancer stem cell-like property through epigenetic reprogramming: A novel mechanism of metal carcinogenesis. <i>Seminars in Cancer Biology</i> , 2019, 57, 95-104.	4.3	57
363	ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells. <i>Experimental and Molecular Pathology</i> , 2019, 106, 116-122.	0.9	28
364	TGF- β 2-induced alternative splicing of TAK1 promotes EMT and drug resistance. <i>Oncogene</i> , 2019, 38, 3185-3200.	2.6	64
365	SNHG20: A vital lncRNA in multiple human cancers. <i>Journal of Cellular Physiology</i> , 2019, 234, 14519-14525.	2.0	51
366	Desferrioxamine-caffeine shows improved efficacy in chelating iron and depleting cancer stem cells. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 52, 232-238.	1.5	14
367	TGF- β 2-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. <i>Cancer Research</i> , 2019, 79, 33-46.	0.4	70
368	Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. <i>Biomaterials</i> , 2019, 192, 95-108.	5.7	52
369	Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. <i>Cancer Letters</i> , 2019, 440-441, 23-34.	3.2	17
370	Chromium(VI) promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer. <i>Toxicology Letters</i> , 2019, 300, 10-17.	0.4	17

#	ARTICLE	IF	CITATIONS
371	Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy. Annual Review of Cancer Biology, 2019, 3, 409-428.	2.3	13
372	HSP90: Enabler of Cancer Adaptation. Annual Review of Cancer Biology, 2019, 3, 275-297.	2.3	59
373	LPS promote Osteosarcoma invasion and migration through TLR4/HOTAIR. Gene, 2019, 680, 1-8.	1.0	13
374	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. , 2019, 194, 161-184.		244
375	<scp>ZFAS</scp> 1: A novel vital oncogenic lnc<scp>RNA</scp> in multiple human cancers. Cell Proliferation, 2019, 52, e12513.	2.4	52
376	SOX2 in cancer stemness: tumor malignancy and therapeutic potentials. Journal of Molecular Cell Biology, 2020, 12, 85-98.	1.5	59
377	The CD147â€HYALURONAN Axis in Cancer. Anatomical Record, 2020, 303, 1573-1583.	0.8	21
378	The multifaceted role of mesenchymal stem cells in cancer. Seminars in Cancer Biology, 2020, 60, 225-237.	4.3	112
379	Tumor Dormancy in The Bone. , 2020, , 166-179.		0
380	DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer. Carcinogenesis, 2020, 41, 303-312.	1.3	20
381	The great escape: tumour cell plasticity in resistance to targeted therapy. Nature Reviews Drug Discovery, 2020, 19, 39-56.	21.5	439
382	Role of miRNA sponges in hepatocellular carcinoma. Clinica Chimica Acta, 2020, 500, 10-19.	0.5	72
383	Truncation of MYH8 tail in AML: a novel prognostic marker with increase cell migration and epithelialâ€mesenchymal transition utilizing RAF/MAPK pathway. Carcinogenesis, 2020, 41, 817-827.	1.3	10
384	Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis. Seminars in Cancer Biology, 2020, 60, 181-190.	4.3	26
385	Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Seminars in Cancer Biology, 2020, 60, 202-213.	4.3	83
386	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 2020, 60, 351-361.	4.3	122
387	Targeting cancer stem cells: protons versus photons. British Journal of Radiology, 2020, 93, 20190225.	1.0	9
388	Mitophagy and Mitochondrial Dysfunction in Cancer. Annual Review of Cancer Biology, 2020, 4, 41-60.	2.3	45

#	ARTICLE	IF	CITATIONS
389	Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling. <i>Cancer Research</i> , 2020, 80, 204-218.	0.4	23
390	Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state. <i>International Journal of Cancer</i> , 2020, 146, 2547-2562.	2.3	39
391	Bisphenol A and polychlorinated biphenyls enhance the cancer stem cell properties of human ovarian cancer cells by activating the WNT signaling pathway. <i>Chemosphere</i> , 2020, 246, 125775.	4.2	26
392	Triptolide inhibits CD133 ⁺ /CD44 ⁺ colon cancer stem cell growth and migration through triggering apoptosis and represses epithelial→mesenchymal transition via downregulating expressions of snail, slug, and twist. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3313-3324.	1.2	31
393	ATP6L promotes metastasis of colorectal cancer by inducing epithelial→mesenchymal transition. <i>Cancer Science</i> , 2020, 111, 477-488.	1.7	10
394	A pre-existing population of ZEB2 ⁺ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 2.	3.5	56
395	Antitumor functions and mechanisms of nitidine chloride in human cancers. <i>Journal of Cancer</i> , 2020, 11, 1250-1256.	1.2	33
396	Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. <i>Nature Communications</i> , 2020, 11, 220.	5.8	59
397	A multi-functional drug delivery system based on polyphenols for efficient tumor inhibition and metastasis prevention. <i>Biomaterials Science</i> , 2020, 8, 702-711.	2.6	31
398	Graphene Oxide Promotes Cancer Metastasis through Associating with Plasma Membrane To Promote TGF- β 2 Signaling-Dependent Epithelial→Mesenchymal Transition. <i>ACS Nano</i> , 2020, 14, 818-827.	7.3	43
399	HOXB5 promotes malignant progression in pancreatic cancer via the miR-6732 pathway. <i>Cell Cycle</i> , 2020, 19, 233-245.	1.3	8
400	The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells. <i>RNA Biology</i> , 2020, 17, 1576-1589.	1.5	43
401	Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 256-266.	1.2	22
402	A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells. <i>Cancer Research</i> , 2020, 80, 418-429.	0.4	44
403	Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy. <i>Theranostics</i> , 2020, 10, 1181-1196.	4.6	81
404	KrÄppel-like factor 4 regulates stemness and mesenchymal properties of colorectal cancer stem cells through the TGF- β 1/Smad/snail pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1866-1877.	1.6	32
405	Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drug-Surviving Cancer Cells. <i>Advanced Biology</i> , 2020, 4, 1900213.	3.0	8
406	The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 288-300.	1.7	30

#	ARTICLE	IF	CITATIONS
407	Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2020, 8, 179-191.	1.6	91
408	Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 615-629.	1.1	31
409	Dual and multi-targeted nanoparticles for site-specific brain drug delivery. <i>Journal of Controlled Release</i> , 2020, 317, 195-215.	4.8	72
410	GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. <i>Oncimmunology</i> , 2020, 9, 1683345.	2.1	54
411	Fibronectin in Cancer: Friend or Foe. <i>Cells</i> , 2020, 9, 27.	1.8	108
412	ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer. <i>Pharmaceuticals</i> , 2020, 13, 1.	1.7	75
413	A Marine Collagen-Based Biomimetic Hydrogel Recapitulates Cancer Stem Cell Niche and Enhances Progression and Chemoresistance in Human Ovarian Cancer. <i>Marine Drugs</i> , 2020, 18, 498.	2.2	9
414	Cancer Stem Cells: New Horizons in Cancer Therapies. , 2020, , .		1
415	Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell. <i>Oncogene</i> , 2020, 39, 7265-7278.	2.6	30
416	Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. <i>Journal of Hematology and Oncology</i> , 2020, 13, 136.	6.9	128
417	Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. <i>PLoS ONE</i> , 2020, 15, e0226464.	1.1	13
418	Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics. <i>PLoS Pathogens</i> , 2020, 16, e1008660.	2.1	4
419	Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight. <i>Frontiers in Oncology</i> , 2020, 10, 579464.	1.3	9
420	Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. <i>Cells</i> , 2020, 9, 2308.	1.8	211
421	Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer. <i>Cellular Signalling</i> , 2020, 76, 109810.	1.7	26
422	MicroRNA-7 targets T-Box 2 to inhibit epithelial-mesenchymal transition and invasiveness in glioblastoma multiforme. <i>Cancer Letters</i> , 2020, 493, 133-142.	3.2	18
423	Activation of the RhoA/ROCK pathway contributes to renal fibrosis in offspring rats induced by maternal exposure to di-n-butyl phthalate. <i>Toxicology</i> , 2020, 443, 152573.	2.0	8
424	Annurca apple polyphenol extract promotes mesenchymal-to-epithelial transition and inhibits migration in triple-negative breast cancer cells through ROS/JNK signaling. <i>Scientific Reports</i> , 2020, 10, 15921.	1.6	23

#	ARTICLE	IF	CITATIONS
425	<p>circKRT7-miR-29a-3p-COL1A1 Axis Promotes Ovarian Cancer Cell Progression<p>. OncoTargets and Therapy, 2020, Volume 13, 8963-8976.	1.0	31
426	Expression and Clinicopathological Significances of lncRNAs: Could ARA and ZEB2NAT be the Potential Breast Cancer-Related Biomarkers?. Archives of Medical Research, 2020, 51, 851-859.	1.5	2
427	A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. International Journal of Molecular Sciences, 2020, 21, 7304.	1.8	11
428	Berberine modulates Keratin 17 to inhibit cervical cancer cell viability and metastasis. Journal of Receptor and Signal Transduction Research, 2021, 41, 521-531.	1.3	11
429	Lipid Phosphate Phosphatases and Cancer. Biomolecules, 2020, 10, 1263.	1.8	27
431	Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 2020, 5, 228.	7.1	120
432	The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/ β -catenin signaling pathway. Cellular and Molecular Immunology, 2020, 17, 1163-1179.	4.8	40
433	Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. Gastroenterology Report, 2020, 8, 390-398.	0.6	25
434	TGF- β 2 causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics, 2020, 10, 7656-7670.	4.6	34
435	Fractionated radiation promotes proliferation and radioresistance in bystander A549 cells but not in bystander HT29 cells. Life Sciences, 2020, 257, 118087.	2.0	3
436	PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR. Frontiers in Oncology, 2020, 10, 1067.	1.3	15
437	Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell International, 2020, 20, 288.	1.8	22
438	Colorectal Cancer Stem Cells in the Progression to Liver Metastasis. Frontiers in Oncology, 2020, 10, 1511.	1.3	28
439	Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma. International Journal of Medical Sciences, 2020, 17, 1598-1609.	1.1	9
440	Epithelial-mesenchymal transition in cancer. , 2020, , 553-568.		1
441	A-kinase interacting protein 1 high expression correlates with advanced tumor stage and poor overall survival in surgical patients with clear cell renal cell carcinoma. Medicine (United States), 2020, 99, e20742.	0.4	5
442	Twist-mediated PAR1 induction is required for breast cancer progression and metastasis by inhibiting Hippo pathway. Cell Death and Disease, 2020, 11, 520.	2.7	29
443	Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis. Molecular Oncology, 2020, 14, 2796-2813.	2.1	21

#	ARTICLE	IF	CITATIONS
444	A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8405.	1.8	14
445	Long Non-coding RNA LINC01503 Promotes Gastric Cardia Adenocarcinoma Progression via miR-133a-5p/VIM Axis and EMT Process. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3391-3403.	1.1	8
446	Environmental chemicals, breast cancer progression and drug resistance. <i>Environmental Health</i> , 2020, 19, 117.	1.7	91
447	A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. <i>Cell Death and Disease</i> , 2020, 11, 982.	2.7	1
448	<p>Inhibition of Yes-Associated Protein-1 (YAP1) Enhances the Response of Invasive Breast Cancer Cells to the Standard Therapy</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 189-199.	1.0	9
449	CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress. <i>Breast Cancer Research</i> , 2020, 22, 125.	2.2	5
450	Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy. <i>Cancers</i> , 2020, 12, 3461.	1.7	33
451	Actin cytoskeleton in mesenchymal-to-amoeboid transition of cancer cells. <i>International Review of Cell and Molecular Biology</i> , 2020, 356, 197-256.	1.6	22
452	Recent developments in unraveling signaling mechanisms underlying drug resistance due to cancer stem-like cells. <i>Current Opinion in Pharmacology</i> , 2020, 54, 130-141.	1.7	8
453	LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2. <i>Cancer Cell International</i> , 2020, 20, 569.	1.8	22
454	Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy. <i>Seminars in Cancer Biology</i> , 2022, 81, 145-159.	4.3	41
455	The Cellular Prion Protein: A Promising Therapeutic Target for Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9208.	1.8	19
456	Evaluation of epithelial and mesenchymal cell markers in canine urinary bladder transitional cell carcinoma. <i>Veterinary Journal</i> , 2020, 266, 105571.	0.6	4
457	The PKC universe keeps expanding: From cancer initiation to metastasis. <i>Advances in Biological Regulation</i> , 2020, 78, 100755.	1.4	16
458	AUF1 promotes stemness in human mammary epithelial cells through stabilization of the EMT transcription factors TWIST1 and SNAIL1. <i>Oncogenesis</i> , 2020, 9, 70.	2.1	15
459	Cancer Stem Cells"Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 1280.	2.2	444
460	Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	14
461	<p>Long Non-Coding RNAs in Drug Resistance of Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7075-7087.	1.0	20

#	ARTICLE	IF	CITATIONS
462	Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153158.	1.0	8
463	HNF4 α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. <i>Nature Communications</i> , 2020, 11, 3978.	5.8	73
464	EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment. <i>Cancers</i> , 2020, 12, 2154.	1.7	56
465	High expression of miR-135b predicts malignant transformation and poor prognosis of gastric cancer. <i>Life Sciences</i> , 2020, 257, 118133.	2.0	18
466	Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer-derived extracellular vesicles. <i>International Journal of Cancer</i> , 2020, 147, 2924-2933.	2.3	23
467	Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1122.	1.3	18
468	ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 2255.	1.0	12
469	The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 613.	1.8	13
470	13-Acetoxy sarcocrossolide Exhibits Cytotoxic Activity against Oral Cancer Cells through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical Concepts. <i>Marine Drugs</i> , 2020, 18, 382.	2.2	23
471	Targeting EMT in Cancer with Repurposed Metabolic Inhibitors. <i>Trends in Cancer</i> , 2020, 6, 942-950.	3.8	146
472	Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?. <i>Frontiers in Oncology</i> , 2020, 10, 1084.	1.3	55
473	The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP/TAZ and TGF β Signaling. <i>Cancers</i> , 2020, 12, 2047.	1.7	10
474	Long non-coding RNA (lncRNA) and epithelial-mesenchymal transition (EMT) in colorectal cancer: a systematic review. <i>Cancer Biology and Therapy</i> , 2020, 21, 769-781.	1.5	28
475	CDYL2 Epigenetically Regulates MIR124 to Control NF- κ B/STAT3-Dependent Breast Cancer Cell Plasticity. <i>IScience</i> , 2020, 23, 101141.	1.9	22
476	Histamine H4 receptor agonists induce epithelial-mesenchymal transition events and enhance mammosphere formation via Src and TGF- β signaling in breast cancer cells. <i>Biochemical Pharmacology</i> , 2020, 180, 114177.	2.0	11
477	DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression. <i>Theranostics</i> , 2020, 10, 8903-8923.	4.6	16
478	A new approach to epithelial-mesenchymal transition diagnostics in epithelial tumors: double immunofluorescent staining and flow cytometry. <i>BioTechniques</i> , 2020, 69, 257-263.	0.8	15
479	Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity. <i>Annals of Translational Medicine</i> , 2020, 8, 905-905.	0.7	15

#	ARTICLE	IF	CITATIONS
480	Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. <i>Cell Systems</i> , 2020, 11, 196-207.e7.	2.9	24
481	Polypliod Giant Cancer Cells, a Hallmark of Oncoviruses and a New Therapeutic Challenge. <i>Frontiers in Oncology</i> , 2020, 10, 567116.	1.3	39
482	Stemness Related Genes Revealed by Network Analysis Associated With Tumor Immune Microenvironment and the Clinical Outcome in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 549213.	1.1	47
484	Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. <i>Nature Communications</i> , 2020, 11, 5017.	5.8	28
485	<p>Structural and Functional Overview of TEAD4 in Cancer Biology</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 9865-9874.	1.0	30
486	Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7469.	1.8	5
487	Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 249.	7.1	88
488	Regulation of Epithelialâ€Mesenchymal Plasticity by the E3 Ubiquitin-Ligases in Cancer. <i>Cancers</i> , 2020, 12, 3093.	1.7	9
489	Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines. <i>Theranostics</i> , 2020, 10, 9601-9618.	4.6	28
490	Autophagy-mediating microRNAs in cancer chemoresistance. <i>Cell Biology and Toxicology</i> , 2020, 36, 517-536.	2.4	22
491	Modeling Cancer Using Zebrafish Xenografts: Drawbacks for Mimicking the Human Microenvironment. <i>Cells</i> , 2020, 9, 1978.	1.8	27
492	Epithelialâ€mesenchymal plasticity: emerging parallels between tissue morphogenesis and cancer metastasis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2020, 375, 20200087.	1.8	34
493	Together we stand, apart we fall: how cell-to-cell contact/interplay provides resistance to ferroptosis. <i>Cell Death and Disease</i> , 2020, 11, 789.	2.7	19
494	The anti-tumor effect of ursolic acid on papillary thyroid carcinoma via suppressing Fibronectin-1. <i>Bioscience, Biotechnology and Biochemistry</i> , 2020, 84, 2415-2424.	0.6	6
495	Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies. <i>Cancer Research</i> , 2020, 80, 5147-5154.	0.4	11
496	Cancer stem cell generation during epithelial-mesenchymal transition is temporally gated by intrinsic circadian clocks. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 617-635.	1.7	19
497	Peritoneal Metastatic Cancer Stem Cells of Gastric Cancer with Partial Mesenchymal-Epithelial Transition and Enhanced Invasiveness in an Intraperitoneal Transplantation Model. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-13.	0.7	3
498	Advances in Gold Nanoparticle-Based Combined Cancer Therapy. <i>Nanomaterials</i> , 2020, 10, 1671.	1.9	60

#	ARTICLE	IF	CITATIONS
499	YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2. <i>International Journal of Clinical Oncology</i> , 2020, 25, 2055-2065.	1.0	7
500	Iron and Cancer: 2020 Vision. <i>Cancer Research</i> , 2020, 80, 5435-5448.	0.4	91
501	Deficiency of pseudogene UPAT leads to hepatocellular carcinoma progression and forms a positive feedback loop with ZEB1. <i>Cancer Science</i> , 2020, 111, 4102-4117.	1.7	6
502	Discovery of epi-Enprioline as a Novel Drug for the Treatment of Vincristine Resistant Neuroblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6577.	1.8	3
503	CircRNAs in anticancer drug resistance: recent advances and future potential. <i>Molecular Cancer</i> , 2020, 19, 127.	7.9	68
504	The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells. <i>Journal of Molecular Medicine</i> , 2020, 98, 1431-1446.	1.7	58
505	Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. <i>Genes</i> , 2020, 11, 922.	1.0	46
506	Recent advance in near-infrared/ultrasound-sensitive 2D-nanomaterials for cancer therapeutics. <i>Science China Materials</i> , 2020, 63, 2397-2428.	3.5	56
507	The glutathione peroxidase 8 (GPX8)/IL-6/STAT3 axis is essential in maintaining an aggressive breast cancer phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21420-21431.	3.3	36
508	Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1. <i>Oncogene</i> , 2020, 39, 6218-6230.	2.6	16
509	SP8 Promotes an Aggressive Phenotype in Hepatoblastoma via FGF8 Activation. <i>Cancers</i> , 2020, 12, 2294.	1.7	14
510	Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9457.	1.8	56
511	Extracellular Vesicles: Messengers of p53 in Tumor-Stroma Communication and Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9648.	1.8	23
512	Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization. <i>Cell Death and Disease</i> , 2020, 11, 1073.	2.7	11
513	The Antiasthma Medication Ciclesonide Suppresses Breast Cancer Stem Cells through Inhibition of the Glucocorticoid Receptor Signaling-Dependent YAP Pathway. <i>Molecules</i> , 2020, 25, 6028.	1.7	9
514	Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 596239.	1.6	20
515	Tumor Hypoxia and Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9592.	1.8	17
516	Clinicopathological Significances of Cancer Stem Cell-Associated HHEX Expression in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 605744.	1.8	15

#	ARTICLE	IF	CITATIONS
517	Cyclin F Downregulation Affects Epithelial-Mesenchymal Transition Increasing Proliferation and Migration of the A-375 Melanoma Cell Line. <i>Cancer Management and Research</i> , 2020, Volume 12, 13085-13097.	0.9	4
518	SATB2: A versatile transcriptional regulator of craniofacial and skeleton development, neurogenesis and tumorigenesis, and its applications in regenerative medicine. <i>Genes and Diseases</i> , 2022, 9, 95-107.	1.5	16
519	Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 276.	3.5	14
520	The Intimate Relationship among EMT, MET and TME: A Transdifferentiation Enhancing Mixture to Be Exploited for Therapeutic Purposes. <i>Cancers</i> , 2020, 12, 3674.	1.7	35
521	Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines. <i>Cells</i> , 2020, 9, 2596.	1.8	16
522	The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3912.	1.0	6
523	A Novel Six-Gene Signature for Prognosis Prediction in Ovarian Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 1006.	1.1	13
524	Differentiation of Cancer Stem Cells through Nanoparticle Surface Engineering. <i>ACS Nano</i> , 2020, 14, 15276-15285.	7.3	33
525	Dopamine D1 Receptor in Cancer. <i>Cancers</i> , 2020, 12, 3232.	1.7	20
526	Identification of cancer stem cell-related biomarkers in intestinal-type and diffuse-type gastric cancer by stemness index and weighted correlation network analysis. <i>Journal of Translational Medicine</i> , 2020, 18, 418.	1.8	8
527	Alternative Checkpoints as Targets for Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 126.	1.8	12
528	Inhibition of PIM1 attenuates the stem cell-like traits of breast cancer cells by promoting RUNX3 nuclear retention. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6308-6323.	1.6	8
529	The Glioma Stem Cell Model in the Era of Single-Cell Genomics. <i>Cancer Cell</i> , 2020, 37, 630-636.	7.7	153
530	Cancer Stem Cell Plasticity – A Deadly Deal. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 79.	1.6	106
531	Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer. <i>Diagnostics</i> , 2020, 10, 305.	1.3	7
532	Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells. <i>Journal of Clinical Medicine</i> , 2020, 9, 1502.	1.0	23
533	PDPN Is Expressed in Various Types of Canine Tumors and Its Silencing Induces Apoptosis and Cell Cycle Arrest in Canine Malignant Melanoma. <i>Cells</i> , 2020, 9, 1136.	1.8	13
534	Role of Platelet Type Lectin-Like Receptor 2 in Promoting Lung Metastasis in Osteosarcoma. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1738-1750.	3.1	16

#	ARTICLE	IF	CITATIONS
535	Bioinformatics Analysis Reveals Biomarkers With Cancer Stem Cell Characteristics in Lung Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 427.	1.1	62
536	Metabolic reprogramming in triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 44-59.	1.4	78
537	STIM1 is a metabolic checkpoint regulating the invasion and metastasis of hepatocellular carcinoma. <i>Theranostics</i> , 2020, 10, 6483-6499.	4.6	42
538	Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 63.	1.6	38
539	DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 24-36.	2.0	31
540	Key Regulatory miRNAs and their Interplay with Mechanosensing and Mechanotransduction Signaling Pathways in Breast Cancer Progression. <i>Molecular Cancer Research</i> , 2020, 18, 1113-1128.	1.5	8
541	Hypoxia-induced epithelial to mesenchymal transition in cancer. <i>Cancer Letters</i> , 2020, 487, 10-20.	3.2	86
542	Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications. <i>Cancers</i> , 2020, 12, 1339.	1.7	51
543	miR-410 induces both epithelial to mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 85.	7.1	48
544	A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations. <i>Frontiers in Oncology</i> , 2020, 10, 928.	1.3	61
545	Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118782.	1.9	41
546	Regulation of breast cancer metastasis signaling by miRNAs. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 837-886.	2.7	87
547	Effects of different levels of TGF- β 2 expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 23, 100299.	1.0	7
548	The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1501-1511.	1.1	13
549	Tailored Functionalized Magnetic Nanoparticles to Target Breast Cancer Cells Including Cancer Stem-Like Cells. <i>Cancers</i> , 2020, 12, 1397.	1.7	13
550	Epithelial to Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. <i>Molecular Cancer Research</i> , 2020, 18, 1257-1270.	1.5	86
551	The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness. <i>Cancers</i> , 2020, 12, 1582.	1.7	26
552	Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 112.	3.5	158

#	ARTICLE	IF	CITATIONS
553	Role of Exosomal miRNAs and the Tumor Microenvironment in Drug Resistance. <i>Cells</i> , 2020, 9, 1450.	1.8	65
554	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1673-1697.	2.0	38
555	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. <i>Cells</i> , 2020, 9, 1402.	1.8	46
556	EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells. <i>Scientific Reports</i> , 2020, 10, 9275.	1.6	18
557	Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 764.	1.3	70
558	RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. <i>Journal of Cellular Physiology</i> , 2020, 235, 7261-7272.	2.0	34
559	Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. <i>Cancer Discovery</i> , 2020, 10, 854-871.	7.7	54
560	Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. <i>Molecular Cancer</i> , 2020, 19, 58.	7.9	124
561	<p>Leucine Zipper-EF-Hand Containing Transmembrane Protein 1 Is a Potential Prognostic Biomarker and Promotes Cell Progression in Prostate Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1649-1660.	0.9	9
562	PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma. <i>Theranostics</i> , 2020, 10, 3151-3163.	4.6	37
563	Correlation between FAK and EGF-Induced EMT in Colorectal Cancer Cells. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	22
564	A Novel Model of Cancer Drug Resistance: Oncosomal Release of Cytotoxic and Antibody-Based Drugs. <i>Biology</i> , 2020, 9, 47.	1.3	20
565	Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. <i>Advanced Science</i> , 2020, 7, 1903483.	5.6	33
566	A plausible accelerating function of intermediate states in cancer metastasis. <i>PLoS Computational Biology</i> , 2020, 16, e1007682.	1.5	38
567	Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma. <i>Journal of Cell Communication and Signaling</i> , 2020, 14, 389-402.	1.8	19
568	Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 746.	1.8	86
569	ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 36.	1.6	112
570	Methodology to analyze gene expression patterns of early mammary development in pig models. <i>Molecular Biology Reports</i> , 2020, 47, 3241-3248.	1.0	4

#	ARTICLE	IF	CITATIONS
571	TNFAIP8 promotes the migration of clear cell renal cell carcinoma by regulating the EMT. <i>Journal of Cancer</i> , 2020, 11, 3061-3071.	1.2	14
572	<p>FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1625-1635.	1.0	36
573	Cancer Stem Cells: Devil or Savior"Looking behind the Scenes of Immunotherapy Failure. <i>Cells</i> , 2020, 9, 555.	1.8	26
574	Vimentin-targeting AIEgen-peptide conjugates: Wash-free fluorescence detection of EMT-type cancer cells and tissues. <i>Sensors and Actuators B: Chemical</i> , 2020, 321, 128536.	4.0	11
575	ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1080.	1.3	21
576	CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer. <i>British Journal of Cancer</i> , 2020, 123, 1131-1144.	2.9	10
577	MicroRNAs Modulate Drug Resistance-Related Mechanisms in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 920.	1.3	27
578	Aneuploid Circulating Tumor-Derived Endothelial Cell (CTEC): A Novel Versatile Player in Tumor Neovascularization and Cancer Metastasis. <i>Cells</i> , 2020, 9, 1539.	1.8	42
579	<p>Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Adenocarcinoma Cells "Role of Snail, Slug and Twist and Small Molecule Inhibitors</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5763-5777.	1.0	11
580	<p>Expression Level of Wnt5a Was Related to the Therapeutic Effects of First-Generation EGFR-TKIs</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5387-5394.	1.0	1
581	Overcoming cancer therapeutic bottleneck by drug repurposing. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 113.	7.1	299
582	The Fire Within: NF- κ B Involvement in Non"Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 4025-4036.	0.4	34
583	Exosomal Noncoding RNAs and Tumor Drug Resistance. <i>Cancer Research</i> , 2020, 80, 4307-4313.	0.4	27
584	EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis. <i>Cancers</i> , 2020, 12, 1632.	1.7	74
585	Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma. <i>Cell</i> , 2020, 182, 497-514.e22.	13.5	508
586	Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF- κ B/STAT3-regulated proteins. <i>Cell Death and Disease</i> , 2020, 11, 477.	2.7	47
587	3D culture technologies of cancer stem cells: promising ex vivo tumor models. <i>Journal of Tissue Engineering</i> , 2020, 11, 204173142093340.	2.3	47
589	Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State. <i>Cells</i> , 2020, 9, 1572.	1.8	17

#	ARTICLE	IF	CITATIONS
590	Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies. <i>Frontiers in Pharmacology</i> , 2020, 11, 904.	1.6	99
591	Lipidome-based rapid diagnosis with machine learning for detection of TGF- β 2 signalling activated area in head and neck cancer. <i>British Journal of Cancer</i> , 2020, 122, 995-1004.	2.9	9
592	Blood platelets stimulate cancer extravasation through TGF β 2-mediated downregulation of PRH/HHEX. <i>Oncogenesis</i> , 2020, 9, 10.	2.1	27
593	Identification of a Zeb1 expressing basal stem cell subpopulation in the prostate. <i>Nature Communications</i> , 2020, 11, 706.	5.8	42
594	The FDA-Approved Anti-Asthma Medicine Ciclesonide Inhibits Lung Cancer Stem Cells through Hedgehog Signaling-Mediated SOX2 Regulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1014.	1.8	14
595	Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemo-resistance. <i>Cells</i> , 2020, 9, 428.	1.8	111
596	<p>Nucleolar and Spindle Associated Protein 1 (NUSAP1) Promotes Bladder Cancer Progression Through the TGF- β 2 Signaling Pathway</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 813-825.	1.0	18
597	Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 487.	1.7	29
598	Kinobead/LC-MS Phosphokinome Profiling Enables Rapid Analyses of Kinase-Dependent Cell Signaling Networks. <i>Journal of Proteome Research</i> , 2020, 19, 1235-1247.	1.8	7
599	Tracing tumorigenesis in a solid tumor model at single-cell resolution. <i>Nature Communications</i> , 2020, 11, 991.	5.8	44
600	Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1334.	1.8	20
601	Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance. <i>Trends in Cancer</i> , 2020, 6, 319-336.	3.8	401
602	Salinomycin Derivatives Kill Breast Cancer Stem Cells by Lysosomal Iron Targeting. <i>Chemistry - A European Journal</i> , 2020, 26, 7416-7424.	1.7	57
603	Estrogen-related receptor β promotes gallbladder cancer development by enhancing the transcription of Nectin β . <i>Cancer Science</i> , 2020, 111, 1514-1527.	1.7	17
604	Hepatocellular Carcinoma Cells with Downregulated ZEB2 Become Resistant to Resveratrol by Concomitant Induction of ABCG2 Expression. <i>Molecular Biology</i> , 2020, 54, 75-81.	0.4	4
605	Lysosomal-targeted anticancer half-sandwich iridium(III) complexes modified with lonidamine amide derivatives. <i>Applied Organometallic Chemistry</i> , 2020, 34, e5589.	1.7	11
606	Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. <i>Drug Resistance Updates</i> , 2020, 50, 100683.	6.5	90
607	miR-125b lowers sensitivity to apoptosis following mitotic arrest: Implications for breast cancer therapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 6335-6344.	2.0	11

#	ARTICLE	IF	CITATIONS
608	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020, 37, 104-122.e12.	7.7	267
609	Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 4308-4322.	4.0	115
610	DNA damage response and resistance of cancer stem cells. <i>Cancer Letters</i> , 2020, 474, 106-117.	3.2	87
611	Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells. <i>Cancers</i> , 2020, 12, 196.	1.7	6
612	Tactics of cancer invasion: solitary and collective invasion. <i>Journal of Biochemistry</i> , 2020, 167, 347-355.	0.9	30
613	AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. <i>Cells</i> , 2020, 9, 247.	1.8	25
614	Aurora B induces epithelial-to-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis. <i>Oncogene</i> , 2020, 39, 2550-2567.	2.6	24
615	Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. <i>Cancer Research</i> , 2020, 80, 1551-1563.	0.4	40
616	EMT signaling: potential contribution of CRISPR/Cas gene editing. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2701-2722.	2.4	22
617	Role of Rad51 and DNA repair in cancer: A molecular perspective. , 2020, 208, 107492.		64
618	Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-to-Mesenchymal Transition. <i>Cells</i> , 2020, 9, 217.	1.8	252
619	Metabolic Symbiosis in Chemoresistance: Refocusing the Role of Aerobic Glycolysis. <i>Frontiers in Oncology</i> , 2020, 10, 5.	1.3	73
620	<p>FOXP1, Regulated by miR-365-3p, Promotes Cell Growth and EMT Indicates Unfavorable Prognosis in Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 623-634.	1.0	23
621	The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells. <i>International Journal of Biological Sciences</i> , 2020, 16, 598-610.	2.6	32
622	The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 47.	1.3	9
623	Novel Therapeutic Strategies for Ovarian Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 319.	1.3	44
624	The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 526.	2.2	30
625	^{low}/^{high} signature in non-small cell lung cancer is predictive of ^{anti-HER2} molecule efficacy. <i>Journal of Pathology</i> , 2020, 251, 187-199.	2.1	12

#	ARTICLE	IF	CITATIONS
626	EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 612-617.	1.0	8
627	ROS and oncogenesis with special reference to EMT and stemness. <i>European Journal of Cell Biology</i> , 2020, 99, 151073.	1.6	69
628	Simultaneous inhibition of CXCR1/2, TGF- β 2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
629	Weighted Gene Coexpression Network Analysis of Features That Control Cancer Stem Cells Reveals Prognostic Biomarkers in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 311.	1.1	99
630	Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2780.	1.8	24
631	Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. <i>Translational Oncology</i> , 2020, 13, 100773.	1.7	455
632	ERK1/2-Nanog signaling pathway enhances CD44(+) cancer stem-like cell phenotypes and epithelial-to-mesenchymal transition in head and neck squamous cell carcinomas. <i>Cell Death and Disease</i> , 2020, 11, 266.	2.7	48
633	Cinobufacini Inhibits Colon Cancer Invasion and Metastasis via Suppressing Wnt/ β 2-Catenin Signaling Pathway and EMT. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 703-718.	1.5	80
634	KRT6A Promotes EMT and Cancer Stem Cell Transformation in Lung Adenocarcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382092124.	0.8	38
635	Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment. <i>Surgical Oncology</i> , 2020, 34, 154-162.	0.8	13
636	The Role of Exosomal microRNA in Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 472.	1.3	36
637	The role of miRNA biogenesis and DDX17 in tumorigenesis and cancer stemness. <i>Biomedical Journal</i> , 2020, 43, 107-114.	1.4	54
638	Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index. <i>Cancer Medicine</i> , 2020, 9, 4290-4298.	1.3	74
639	Intravenous 5-fluoro-2â€²-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 979-993.	1.1	13
640	Plasticity in Motion: Shape-Shifting Lgr5âˆ«Cells Initiate Colorectal Cancer Metastasis. <i>Cell Stem Cell</i> , 2020, 26, 469-471.	5.2	3
641	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. <i>Nature Communications</i> , 2020, 11, 1923.	5.8	79
642	Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 801-810.	1.5	48
643	Integrin β 4â€«Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis. <i>Cancer Research</i> , 2020, 80, 771-783.	0.4	48

#	ARTICLE	IF	CITATIONS
644	Molecular avenues in targeted doxorubicin cancer therapy. <i>Future Oncology</i> , 2020, 16, 687-700.	1.1	28
645	Regulation of Integrin Subunit Alpha 2 by miR-135b-5p Modulates Chemoresistance in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 308.	1.3	27
646	Zebrafish Microenvironment Elevates EMT and CSC-Like Phenotype of Engrafted Prostate Cancer Cells. <i>Cells</i> , 2020, 9, 797.	1.8	12
647	Calcium Channels as Novel Therapeutic Targets for Ovarian Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2327.	1.8	35
648	Mathematical and Systems Medicine Approaches to Resistance Evolution and Prevention in Cancer. , 2021, , 247-260.		0
649	Overexpression of RRM2 is related to poor prognosis in oral squamous cell carcinoma. <i>Oral Diseases</i> , 2021, 27, 204-214.	1.5	19
650	Genomic control of metastasis. <i>British Journal of Cancer</i> , 2021, 124, 3-12.	2.9	27
651	Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1983-2000.	2.4	11
652	Continuous formation of small clusters with LGR5-positive cells contributes to tumor growth in a colorectal cancer xenograft model. <i>Laboratory Investigation</i> , 2021, 101, 12-25.	1.7	2
653	The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. <i>Cellular and Molecular Immunology</i> , 2021, 18, 711-722.	4.8	54
654	TGF β 2 biology in cancer progression and immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 9-34.	12.5	420
655	Challenges and Opportunities in Cancer Drug Resistance. <i>Chemical Reviews</i> , 2021, 121, 3297-3351.	23.0	203
656	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 281-289.	2.9	22
657	Biological roles of piRNAs in colorectal cancer. <i>Gene</i> , 2021, 769, 145063.	1.0	4
658	Curcumin: A therapeutic strategy for colorectal cancer?. <i>Seminars in Cancer Biology</i> , 2021, 73, 321-330.	4.3	31
659	Inhibition of p70 isoforms of S6K1 induces anoikis to prevent transformed human hepatocyte growth. <i>Life Sciences</i> , 2021, 265, 118764.	2.0	9
660	Sustained high expression of NRF2 and its target genes induces dysregulation of cellular proliferation and apoptosis is associated with arsenite-induced malignant transformation of human bronchial epithelial cells. <i>Science of the Total Environment</i> , 2021, 756, 143840.	3.9	14
661	Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells. <i>Journal of Controlled Release</i> , 2021, 330, 1106-1117.	4.8	37

#	ARTICLE	IF	CITATIONS
662	Effect of feedback regulation on stem cell fractions in tissues and tumors: Understanding chemoresistance in cancer. <i>Journal of Theoretical Biology</i> , 2021, 509, 110499.	0.8	7
663	Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188481.	3.3	24
664	Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. <i>Journal of Biological Chemistry</i> , 2021, 296, 100034.	1.6	35
665	Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling. <i>Oncogene</i> , 2021, 40, 922-936.	2.6	20
666	Mutant p53 as a Regulator and Target of Autophagy. <i>Frontiers in Oncology</i> , 2020, 10, 607149.	1.3	32
667	Benzimidazole-Based Organic-Inorganic Gold Nanohybrids Suppress Invasiveness of Cancer Cells by Modulating EMT Signaling Cascade. <i>ACS Applied Bio Materials</i> , 2021, 4, 470-482.	2.3	1
668	Targeting transforming growth factor- β signaling for enhanced cancer chemotherapy. <i>Theranostics</i> , 2021, 11, 1345-1363.	4.6	33
669	The prospects of tumor chemosensitivity testing at the single-cell level. <i>Drug Resistance Updates</i> , 2021, 54, 100741.	6.5	4
670	Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 119-134.	1.3	4
671	Transcriptome analysis of the circadian clock gene BMAL1 deletion with opposite carcinogenic effects. <i>Functional and Integrative Genomics</i> , 2021, 21, 1-16.	1.4	11
672	Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance. <i>FEBS Journal</i> , 2021, 288, 2184-2202.	2.2	10
673	Multifunctional BaMnLuGdF7: Yb/Er/Ho nanoparticles for in vivo tri-modal imaging. <i>Optical Materials</i> , 2021, 111, 110578.	1.7	4
674	lncRNA ϵ -POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 130-142.	1.2	28
675	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. <i>Gut</i> , 2021, 70, 743-760.	6.1	49
676	Ovalitenone Inhibits the Migration of Lung Cancer Cells via the Suppression of AKT/mTOR and Epithelial-to-Mesenchymal Transition. <i>Molecules</i> , 2021, 26, 638.	1.7	6
677	Preventing phenotypic plasticity in cancer to mitigate therapy resistance. , 2021, , 119-160.		0
678	Aldehyde Dehydrogenase 1B1 Is Associated with Altered Cell Morphology, Proliferation, Migration and Chemosensitivity in Human Colorectal Adenocarcinoma Cells. <i>Biomedicines</i> , 2021, 9, 44.	1.4	10
679	Targeting tumor resistance mechanisms. <i>Faculty Reviews</i> , 2021, 10, 6.	1.7	0

#	ARTICLE	IF	CITATIONS
680	Patient-derived organoids in cellulosic sponge model chemotherapy response of metastatic colorectal cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e285.	1.7	6
681	Medicinal Plants of Himalayan Forests. , 2021, , 175-212.		5
682	Role of long non-coding RNA H19 in therapy resistance of digestive system cancers. <i>Molecular Medicine</i> , 2021, 27, 1.	1.9	42
683	Intracranially injectable multi-siRNA nanomedicine for the inhibition of glioma stem cells. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab104.	0.4	5
684	Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. <i>Cellular and Molecular Biology Letters</i> , 2021, 26, 3.	2.7	83
685	Pathophysiological relationship between hypoxia associated oxidative stress, Epithelial-mesenchymal transition, stemness acquisition and alteration of Shh/ Gli-1 axis during oral sub-mucous fibrosis and oral squamous cell carcinoma. <i>European Journal of Cell Biology</i> , 2021, 100, 151146.	1.6	13
686	The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications. <i>International Journal of Biological Sciences</i> , 2021, 17, 2718-2736.	2.6	22
687	Partial EMT in Squamous Cell Carcinoma: A Snapshot. <i>International Journal of Biological Sciences</i> , 2021, 17, 3036-3047.	2.6	26
688	FOXA1 is a determinant of drug resistance in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 317-326.	1.1	12
689	Role of selected phytochemicals on gynecological cancers. , 2021, , 1-30.		0
690	Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer. , 2021, 4, 684-709.		9
691	Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma. <i>Pharmaceutics</i> , 2021, 13, 103.	2.0	8
692	Ephrin A4-ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells. <i>Scientific Reports</i> , 2021, 11, 644.	1.6	9
693	Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8. <i>Anticancer Research</i> , 2021, 41, 187-195.	0.5	4
694	Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. <i>Biomolecules</i> , 2021, 11, 183.	1.8	13
695	MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway. <i>Cell Death and Disease</i> , 2021, 12, 97.	2.7	17
696	Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
697	Identification of Gene Signatures and Expression Patterns During Epithelial-to-Mesenchymal Transition From Single-Cell Expression Atlas. <i>Frontiers in Genetics</i> , 2020, 11, 605012.	1.1	5

#	ARTICLE	IF	CITATIONS
698	Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling. <i>Cancer Research</i> , 2021, 81, 1528-1539.	0.4	5
699	Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. <i>Gut</i> , 2021, 70, 2238-2248.	6.1	30
700	Notch signaling in female cancers: a multifaceted node to overcome drug resistance. , 2021, 4, 805-836.		2
701	CD73, Tumor Plasticity and Immune Evasion in Solid Cancers. <i>Cancers</i> , 2021, 13, 177.	1.7	28
702	TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1121-1143.	2.3	10
703	Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneploid cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	61
704	Flavonoids Targeting Cancer Stem Cells: A Paradigm to Anticancer Efficacy. , 2021, , 239-287.		0
705	Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	0
706	SNU-333 Cells as an Appropriate Cell Line for the Orthotopic Renal Cell Carcinoma Model. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110384.	0.8	2
707	Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	37
708	Epithelial-Mesenchymal Transition Inversely Associates With Immune Activity in Breast Cancer Tumour Immune Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
710	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1301, 7-24.	0.8	1
711	Molecular and therapeutic bases of cancer. , 2021, , 41-98.		0
713	YAP and endothelin-1 signaling: an emerging alliance in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 27.	3.5	23
714	A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. <i>Nature Nanotechnology</i> , 2021, 16, 104-113.	15.6	143
715	Src-1 and SP2 promote the proliferation and epithelialâ€mesenchymal transition of nasopharyngeal carcinoma. <i>Open Medicine (Poland)</i> , 2021, 16, 1061-1069.	0.6	4
716	In Vitro and In Vivo Model Systems of Cholangiocarcinoma. , 2021, , 471-494.		0
717	Ovarian Cancer Stem Cells: Newer Horizons. <i>Journal of Obstetrics and Gynecology of India</i> , 2021, 71, 115-117.	0.3	5

#	ARTICLE	IF	CITATIONS
718	MiRNA-mediated EMT and CSCs in cancer chemoresistance. <i>Experimental Hematology and Oncology</i> , 2021, 10, 12.	2.0	47
719	CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. <i>Molecular Cancer</i> , 2021, 20, 25.	7.9	55
720	The role of Popeye domain-containing protein 1 (POPDC1) in the progression of the malignant phenotype. <i>British Journal of Pharmacology</i> , 2021, , .	2.7	5
721	Plasticity in Colorectal Cancer: Why Cancer Cells Differentiate. <i>Cancers</i> , 2021, 13, 918.	1.7	9
722	Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021, 13, 941.	1.7	20
723	The CD44 ^{high} Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2369.	1.8	12
724	Linking EMT programmes to normal and neoplastic epithelial stem cells. <i>Nature Reviews Cancer</i> , 2021, 21, 325-338.	12.8	273
725	The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 600373.	1.6	3
726	Targeting the tumour microenvironment in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 3-28.	4.3	30
727	Cancer metabolism and intervention therapy. <i>Molecular Biomedicine</i> , 2021, 2, 5.	1.7	20
728	B7-H4 induces epithelial-to-mesenchymal transition and promotes colorectal cancer stemness. <i>Pathology Research and Practice</i> , 2021, 218, 153323.	1.0	11
729	ITPR3 facilitates tumor growth, metastasis and stemness by inducing the NF- κ B/CD44 pathway in urinary bladder carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 65.	3.5	20
730	Mechanisms of resistance to chemotherapy in non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2021, 44, 146-164.	2.7	62
731	Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 619317.	1.3	18
732	Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	0
733	Ginsenoside Rg3 inhibits pulmonary fibrosis by preventing HIF-1 α nuclear localisation. <i>BMC Pulmonary Medicine</i> , 2021, 21, 70.	0.8	14
734	Two novel cell culture models of buccal mucosal oral cancer from patients with no risk-habits of tobacco smoking or chewing. <i>Oral Oncology</i> , 2021, 113, 105131.	0.8	9
735	A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	6

#	ARTICLE	IF	CITATIONS
736	Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2326-2339.	3.2	16
737	Interplay between tumor microenvironment and partial EMT as the driver of tumor progression. <i>IScience</i> , 2021, 24, 102113.	1.9	68
738	Critical Roles of PIWIL1 in Human Tumors: Expression, Functions, Mechanisms, and Potential Clinical Implications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 656993.	1.8	15
739	A novel epithelial-mesenchymal transition molecular signature predicts the oncological outcomes in colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3194-3204.	1.6	8
740	EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression. <i>Oncogenesis</i> , 2021, 10, 26.	2.1	22
741	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. <i>Cancers</i> , 2021, 13, 1538.	1.7	37
742	Vimentin tunes cell migration on collagen by controlling β 1 integrin activation and clustering. <i>Journal of Cell Science</i> , 2021, 134, .	1.2	30
743	Novel Peptide-Based Magnetic Nanoparticle for Mesenchymal Circulating Tumor Cells Detection. <i>Analytical Chemistry</i> , 2021, 93, 5670-5675.	3.2	24
744	Epithelial plasticity, epithelial-mesenchymal transition, and the TGF- β 2 family. <i>Developmental Cell</i> , 2021, 56, 726-746.	3.1	82
745	Single-cell analysis reveals metastatic cell heterogeneity in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4260-4274.	1.6	16
746	Insulin-Like Growth Factor Binding Protein-3 Exerts Its Anti-Metastatic Effect in Aerodigestive Tract Cancers by Disrupting the Protein Stability of Vimentin. <i>Cancers</i> , 2021, 13, 1041.	1.7	10
747	Comprehensive Analysis of the Control of Cancer Stem Cell Characteristics in Endometrial Cancer by Network Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-11.	0.7	5
748	Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. <i>Cancers</i> , 2021, 13, 1118.	1.7	49
749	Vitamin D Regulates CXCL12/CXCR4 and Epithelial-to-Mesenchymal Transition in a Model of Breast Cancer Metastasis to Lung. <i>Endocrinology</i> , 2021, 162, .	1.4	20
750	Nanotechnology-Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002163.	3.9	14
751	Autophagy, an accomplice or antagonist of drug resistance in HCC?. <i>Cell Death and Disease</i> , 2021, 12, 266.	2.7	31
752	CENP-A overexpression promotes distinct fates in human cells, depending on p53 status. <i>Communications Biology</i> , 2021, 4, 417.	2.0	23
753	Knockdown of E-cadherin induces cancer stem-cell-like phenotype and drug resistance in cervical cancer cells. <i>Biochemistry and Cell Biology</i> , 2021, 99, 587-595.	0.9	8

#	ARTICLE	IF	CITATIONS
754	Chemoresistance in Ovarian Cancer: Prospects for New Drugs. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 668-678.	0.9	16
755	Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. <i>Blood</i> , 2021, 137, 3641-3655.	0.6	20
756	Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
757	Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications. <i>Cells</i> , 2021, 10, 678.	1.8	53
758	Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells. <i>Biomedicines</i> , 2021, 9, 297.	1.4	35
759	Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome. <i>Frontiers in Oncology</i> , 2021, 11, 620674.	1.3	14
761	The key roles of cancer stem cell-derived extracellular vesicles. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 109.	7.1	64
762	IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination. <i>Oncogene</i> , 2021, 40, 2200-2216.	2.6	22
763	CUL4B Promotes Breast Carcinogenesis by Coordinating with Transcriptional Repressor Complexes in Response to Hypoxia Signaling Pathway. <i>Advanced Science</i> , 2021, 8, 2001515.	5.6	16
764	circFBXW7 attenuates malignant progression in lung adenocarcinoma by sponging miR-942-5p. <i>Translational Lung Cancer Research</i> , 2021, 10, 1457-1473.	1.3	24
765	CircRNA circ_0092314 Induces Epithelial-Mesenchymal Transition of Pancreatic Cancer Cells via Elevating the Expression of S100P by Sponging miR-671. <i>Frontiers in Oncology</i> , 2021, 11, 675442.	1.3	14
766	SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. <i>Oncogene</i> , 2021, 40, 2539-2552.	2.6	18
767	The AXL-PYK2-PKC δ axis as a nexus of stemness circuits in TNBC. <i>Life Science Alliance</i> , 2021, 4, e202000985.	1.3	7
768	The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells. <i>Scientific Reports</i> , 2021, 11, 9016.	1.6	20
769	Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA β regulation. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 835-850.	1.2	5
770	The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4091.	1.8	14
771	Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters. <i>Cancers</i> , 2021, 13, 2032.	1.7	11
772	Communication Between Epithelial-Mesenchymal Plasticity and Cancer Stem Cells: New Insights Into Cancer Progression. <i>Frontiers in Oncology</i> , 2021, 11, 617597.	1.3	23

#	ARTICLE	IF	CITATIONS
773	USP24 promotes drug resistance during cancer therapy. <i>Cell Death and Differentiation</i> , 2021, 28, 2690-2707.	5.0	12
774	The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 650772.	1.8	81
775	Phenotypic heterogeneity, stability and plasticity in tumor-promoting carcinoma-associated fibroblasts. <i>FEBS Journal</i> , 2022, 289, 2429-2447.	2.2	23
776	The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3863.	1.8	31
778	miR-146 connects stem cell identity with metabolism and pharmacological resistance in breast cancer. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	8
779	Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	74
780	Metastasis-Initiating Cells and Ecosystems. <i>Cancer Discovery</i> , 2021, 11, 971-994.	7.7	134
781	Expression and prognostic value of epithelial-mesenchymal transition and cancer stem cell markers in primary lesions and liver metastases of colorectal cancers. <i>Oncology Letters</i> , 2021, 22, 499.	0.8	1
782	Molecular Landscape of the Epithelial-Mesenchymal Transition in Endometrioid Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1520.	1.0	9
783	Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. <i>Pharmacological Research</i> , 2021, 166, 105507.	3.1	28
784	Extracellular matrix and its therapeutic potential for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 153.	7.1	251
785	PKC ζ Inhibition as a Strategy to Sensitize Neuroblastoma Stem Cells to Etoposide by Stimulating Ferroptosis. <i>Antioxidants</i> , 2021, 10, 691.	2.2	20
786	An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 665161.	1.8	7
787	ZEB2 Knock-down Induces Apoptosis in Human Myeloid Leukemia HL-60 Cells. <i>Current Gene Therapy</i> , 2021, 21, 149-159.	0.9	2
788	MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. <i>Cancer Cell International</i> , 2021, 21, 213.	1.8	26
789	A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 2022.	1.7	5
790	Platinum(II) π -heterocyclic carbene complexes arrest metastatic tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
791	Decoding Cancer Biology One Cell at a Time. <i>Cancer Discovery</i> , 2021, 11, 960-970.	7.7	37

#	ARTICLE	IF	CITATIONS
792	Long non-coding RNAs in colorectal cancer: Novel oncogenic mechanisms and promising clinical applications. <i>Cancer Letters</i> , 2021, 504, 67-80.	3.2	32
793	Novel approaches to target the microenvironment of bone metastasis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 488-505.	12.5	91
794	Vimentin regulates the assembly and function of matrix adhesions. <i>Wound Repair and Regeneration</i> , 2021, 29, 602-612.	1.5	30
795	Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. <i>Environmental Toxicology</i> , 2021, 36, 1758-1764.	2.1	10
796	Cancer drug resistance induced by EMT: novel therapeutic strategies. <i>Archives of Toxicology</i> , 2021, 95, 2279-2297.	1.9	92
797	Epithelial-mesenchymal-like transition events in melanoma. <i>FEBS Journal</i> , 2022, 289, 1352-1368.	2.2	54
798	Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5681.	1.8	14
799	Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer. <i>Oncoscience</i> , 2021, 8, 61-71.	0.9	2
800	The many faces of cancer evolution. <i>IScience</i> , 2021, 24, 102403.	1.9	15
801	Ectopic expression of MELK in oral squamous cell carcinoma and its correlation with epithelial mesenchymal transition. <i>Aging</i> , 2021, 13, 13048-13060.	1.4	5
802	Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. <i>Cancers</i> , 2021, 13, 2666.	1.7	79
803	Tumor Extrinsic Factors Mediate Primary T-DM1 Resistance in HER2-Positive Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 2331.	1.7	5
804	Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States. <i>Journal of Clinical Medicine</i> , 2021, 10, 2403.	1.0	30
805	Anti-tumor effects of an ID antagonist with no observed acquired resistance. <i>Npj Breast Cancer</i> , 2021, 7, 58.	2.3	8
806	Fish Oil, Se Yeast, and Micronutrient-Enriched Nutrition as Adjuvant Treatment during Target Therapy in a Murine Model of Lung Cancer. <i>Marine Drugs</i> , 2021, 19, 262.	2.2	6
807	Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. <i>Biomedicines</i> , 2021, 9, 500.	1.4	33
808	Roles and mechanisms of adipokines in drug resistance of tumor cells. <i>European Journal of Pharmacology</i> , 2021, 899, 174019.	1.7	3
809	Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. <i>Frontiers in Immunology</i> , 2021, 12, 656364.	2.2	175

#	ARTICLE	IF	CITATIONS
810	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight, 2021, 6, .	2.3	3
811	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nature Communications, 2021, 12, 2498.	5.8	20
812	Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer, 2021, 21, 632.	1.1	13
813	Small nucleolar <scn>RNA</scn> host genes promoting epithelialâ€“mesenchymal transition lead cancer progression and metastasis. IUBMB Life, 2021, 73, 825-842.	1.5	14
814	The role of CD47-SIRPÎ± immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sciences, 2021, 273, 119150.	2.0	45
815	DCBLD2 Affects the Development of Colorectal Cancer via EMT and Angiogenesis and Modulates 5-FU Drug Resistance. Frontiers in Cell and Developmental Biology, 2021, 9, 669285.	1.8	13
816	Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. EMBO Reports, 2021, 22, e50922.	2.0	20
817	HLA complex group 11 is involved in colorectal carcinoma cisplatin resistance via the miRâ€“214â€“5p/SOX4 axis. Oncology Letters, 2021, 22, 535.	0.8	5
818	MDM2 induces EMT via the Bâ€“Raf signaling pathway through 14â€“3â€“3. Oncology Reports, 2021, 46, .	1.2	5
819	Emerging roles of cancer-testis antigens, semenogelin 1 and 2, in neoplastic cells. Cell Death Discovery, 2021, 7, 97.	2.0	5
820	Role of the ABL tyrosine kinases in the epithelialâ€“mesenchymal transition and the metastatic cascade. Cell Communication and Signaling, 2021, 19, 59.	2.7	17
821	Case study: Digital spatial profiling of metastatic clear cell carcinoma reveals intra-tumor heterogeneity in epithelial-mesenchymal gradient. , 0, , .		1
822	The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 637675.	1.8	69
823	Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell, 2021, 39, 779-792.e11.	7.7	245
824	Endocytosis in the context-dependent regulation of individual and collective cell properties. Nature Reviews Molecular Cell Biology, 2021, 22, 625-643.	16.1	59
825	Tripterygium glycoside suppresses epithelialâ€“toâ€“mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR/Twist1 pathway. Molecular Medicine Reports, 2021, 24, .	1.1	19
826	Cell Plasticity and Prostate Cancer: The Role of Epithelialâ€“Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance. Cancers, 2021, 13, 2795.	1.7	23
827	Genomic Analysis Revealed Mutational Traits Associated with Clinical Outcomes in Osteosarcoma. Cancer Management and Research, 2021, Volume 13, 5101-5111.	0.9	1

#	ARTICLE	IF	CITATIONS
828	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 741-769.	21.5	222
829	Endothelin-1 as a Mediator of Heme Oxygenase-1-Induced Stemness in Colorectal Cancer: Influence of p53. <i>Journal of Personalized Medicine</i> , 2021, 11, 509.	1.1	8
830	Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. <i>Cancers</i> , 2021, 13, 2980.	1.7	8
831	Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5505-5526.	2.4	20
832	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 693609.	2.2	21
833	Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells. <i>Current Medicinal Chemistry</i> , 2022, 29, 741-783.	1.2	12
834	Molecular pathology underlying the robustness of cancer stem cells. <i>Regenerative Therapy</i> , 2021, 17, 38-50.	1.4	18
835	Epithelial-to-Mesenchymal Transition Enhances Cancer Cell Sensitivity to Cytotoxic Effects of Cold Atmospheric Plasmas in Breast and Bladder Cancer Systems. <i>Cancers</i> , 2021, 13, 2889.	1.7	35
836	Pan-cancer network disorders revealed by overall and local signaling entropy. <i>Journal of Molecular Cell Biology</i> , 2021, 13, 622-635.	1.5	2
837	Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of non-small cell lung cancer cells. <i>Oncology Reports</i> , 2021, 46, .	1.2	5
838	Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2987.	1.7	10
839	SOX factors as cell-state regulators in the mammary gland and breast cancer. <i>Seminars in Cell and Developmental Biology</i> , 2021, 114, 126-133.	2.3	14
840	CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 556-566.	1.3	12
841	Alternative splicing associated with cancer stemness in kidney renal clear cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 703.	1.1	15
842	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. <i>Pharmaceuticals</i> , 2021, 14, 559.	1.7	14
843	A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer. <i>Oncogene</i> , 2021, 40, 4906-4918.	2.6	19
844	Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 692940.	1.8	55
845	The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. <i>Npj Precision Oncology</i> , 2021, 5, 56.	2.3	44

#	ARTICLE	IF	CITATIONS
846	Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma. <i>World Journal of Clinical Cases</i> , 2021, 9, 4998-5006.	0.3	8
847	Exosomal lncRNA PVT1/VEGFA Axis Promotes Colon Cancer Metastasis and Stemness by Downregulation of Tumor Suppressor miR-152-3p. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-19.	1.9	28
848	The role of FOSL1 in stem-like cell reprogramming processes. <i>Scientific Reports</i> , 2021, 11, 14677.	1.6	13
849	Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. <i>Gastric Cancer</i> , 2021, 24, 1264-1277.	2.7	20
850	Effect of ISM1 on the Immune Microenvironment and Epithelial-Mesenchymal Transition in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 681240.	1.8	13
851	Tadalafil Reverses the Effect of Three-Dimensional Cell Culture System on Stem Cell Features in A549 and SK-MES-1. <i>DNA and Cell Biology</i> , 2021, 40, 869-880.	0.9	4
852	USP47 maintains the stemness of colorectal cancer cells and is inhibited by parthenolide. <i>Biochemical and Biophysical Research Communications</i> , 2021, 562, 21-28.	1.0	16
853	Preparation of Mitochondria- and Epigenetics-Targeting Nanoparticles for Suppression of Cancer Metastasis. <i>Particle and Particle Systems Characterization</i> , 2021, 38, 2100003.	1.2	0
854	A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy. <i>Pharmaceutics</i> , 2021, 13, 1092.	2.0	14
855	Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 651622.	1.3	17
856	The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 696705.	1.3	13
857	Spelling Out CICs: A Multi-Organ Examination of the Contributions of Cancer Initiating Cells™ Role in Tumor Progression. <i>Stem Cell Reviews and Reports</i> , 2021, , 1.	1.7	1
858	Targeting cancer stem cells by nutraceuticals for cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 85, 234-245.	4.3	16
859	HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. <i>Cancers</i> , 2021, 13, 3575.	1.7	35
860	Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. <i>Cancers</i> , 2021, 13, 3697.	1.7	41
861	Oncogenic functions of ZEB1 in pediatric solid cancers: interplays with microRNAs and long noncoding RNAs. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 4107-4116.	1.4	5
862	Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. <i>Oncogenesis</i> , 2021, 10, 56.	2.1	5
863	Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?. <i>Cancers</i> , 2021, 13, 3351.	1.7	10

#	ARTICLE	IF	CITATIONS
864	FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. <i>Molecular Therapy</i> , 2021, 29, 2583-2600.	3.7	39
865	Translocation of intracellular CD24 constitutes a triggering event for drug resistance in breast cancer. <i>Scientific Reports</i> , 2021, 11, 17077.	1.6	5
866	Cytoskeleton Response to Ionizing Radiation: A Brief Review on Adhesion and Migration Effects. <i>Biomedicines</i> , 2021, 9, 1102.	1.4	10
867	MicroRNA-8063 targets heterogeneous nuclear ribonucleoprotein A2B to inhibit the self-renewal of colorectal cancer stem cells via the Wnt/ β -catenin pathway. <i>Oncology Reports</i> , 2021, 46, .	1.2	9
868	Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression. <i>Frontiers in Oncology</i> , 2021, 11, 730815.	1.3	4
869	Dynamic EMT: a multi-tool for tumor progression. <i>EMBO Journal</i> , 2021, 40, e108647.	3.5	291
870	Modeling the effects of EMT-immune dynamics on carcinoma disease progression. <i>Communications Biology</i> , 2021, 4, 983.	2.0	3
871	The RNA-Binding Protein ESRP1 Modulates the Expression of RAC1b in Colorectal Cancer Cells. <i>Cancers</i> , 2021, 13, 4092.	1.7	6
872	ATF3 inhibits arsenic-induced malignant transformation of human bronchial epithelial cells by attenuating inflammation. <i>Toxicology</i> , 2021, 460, 152890.	2.0	8
873	The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 691-720.	2.7	33
874	Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12877-12892.	2.9	10
875	Improving function of cytotoxic T-lymphocytes by transforming growth factor- β inhibitor in oral squamous cell carcinoma. <i>Cancer Science</i> , 2021, 112, 4037-4049.	1.7	31
876	Molecular and Cellular Insights into the Development of Uterine Fibroids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8483.	1.8	35
877	Ovarian Cancer and Cancer Stem Cells—Cellular and Molecular Characteristics, Signaling Pathways, and Usefulness as a Diagnostic Tool in Medicine and Oncology. <i>Cancers</i> , 2021, 13, 4178.	1.7	10
878	Emerging Role of E2F Family in Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2021, 11, 723137.	1.3	40
879	Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. <i>Cancers</i> , 2021, 13, 3906.	1.7	8
880	SNAI2-Mediated Repression of <i>BIM</i> Protects Rhabdomyosarcoma from Ionizing Radiation. <i>Cancer Research</i> , 2021, 81, 5451-5463.	0.4	13
881	MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 669132.	1.8	8

#	ARTICLE	IF	CITATIONS
882	Silencing the lncRNA NORAD inhibits EMT of head and neck squamous cell carcinoma stem cells via miR-26a-5p. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	7
883	Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 11-29.	1.5	15
884	The FAP-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1288-1304.	5.7	20
885	Knockdown of CXCL5 inhibits the invasion, metastasis and stemness of bladder cancer lung metastatic cells by downregulating CD44. <i>Anti-Cancer Drugs</i> , 2022, 33, e103-e112.	0.7	7
886	Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. <i>Nature Communications</i> , 2021, 12, 4671.	5.8	28
887	Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	2
888	Modulating cell differentiation in cancer models. <i>Biochemical Society Transactions</i> , 2021, 49, 1803-1816.	1.6	2
889	Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer. <i>Lancet Oncology</i> , The, 2021, 22, e358-e368.	5.1	133
890	Heterogeneity within molecular subtypes of breast cancer. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 321, C343-C354.	2.1	43
891	Endocrine regulation of cancer stem cell compartments in breast tumors. <i>Molecular and Cellular Endocrinology</i> , 2021, 535, 111374.	1.6	1
892	CircRNA: A novel potential strategy to treat thyroid cancer (Review). <i>International Journal of Molecular Medicine</i> , 2021, 48, .	1.8	17
893	MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4917.	1.7	17
894	Bridging Tumorigenesis and Therapy Resistance With a Non-Darwinian and Non-Lamarckian Mechanism of Adaptive Evolution. <i>Frontiers in Oncology</i> , 2021, 11, 732081.	1.3	3
895	FOXC1 modulates stem-like cell properties and chemoresistance through Hedgehog and EMT signaling in gastric adenocarcinoma. <i>Molecular Therapy</i> , 2021, , .	3.7	4
896	Novel inhibitor of OCT1 enhances the sensitivity of human esophageal squamous cell carcinoma cells to antitumor agents. <i>European Journal of Pharmacology</i> , 2021, 907, 174222.	1.7	13
897	Microfluidic Tandem Mechanical Sorting System for Enhanced Cancer Stem Cell Isolation and Ingredient Screening. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100985.	3.9	8
898	A direct negative feedback loop of miR-4721/FOXA1/Nanog promotes nasopharyngeal cell stem cell enrichment and metastasis. <i>Journal of Translational Medicine</i> , 2021, 19, 387.	1.8	2
899	The Underappreciated Role of Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease and Its Strong Link to Lung Cancer. <i>Biomolecules</i> , 2021, 11, 1394.	1.8	19

#	ARTICLE	IF	CITATIONS
900	Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis. Cellular and Molecular Bioengineering, 2022, 15, 1-13.	1.0	32
901	Extracellular Vesicles and Cancer Stem Cells in Tumor Progression: New Therapeutic Perspectives. International Journal of Molecular Sciences, 2021, 22, 10572.	1.8	12
902	Sporadic cell death in macroscale 3D tumor grafts with high drug resistance by activating cell-ECM interactions. Biofabrication, 2021, 13, 045022.	3.7	4
903	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 4215-4228.	0.5	7
904	Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Acquire Rejuvenation and Reduced Heterogeneity. Frontiers in Cell and Developmental Biology, 2021, 9, 717772.	1.8	27
905	Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications. European Journal of Pharmacology, 2021, 911, 174546.	1.7	5
906	In Situ Programmable DNA Circuit-Promoted Electrochemical Characterization of Stemlike Phenotype in Breast Cancer. Journal of the American Chemical Society, 2021, 143, 16078-16086.	6.6	30
908	Mediterranean Diet Food Components as Possible Adjuvant Therapies to Counteract Breast and Prostate Cancer Progression to Bone Metastasis. Biomolecules, 2021, 11, 1336.	1.8	4
909	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell, 2021, 39, 1245-1261.e6.	7.7	58
910	Stationed or Relocating: The Seesawing EMT/MET Determinants from Embryonic Development to Cancer Metastasis. Biomedicines, 2021, 9, 1265.	1.4	10
911	Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response. Frontiers in Oncology, 2021, 11, 753330.	1.3	11
912	AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew. Cancers, 2021, 13, 4864.	1.7	22
913	MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer and Metastasis Reviews, 2022, 41, 77-105.	2.7	13
914	Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. Journal of Hematology and Oncology, 2021, 14, 141.	6.9	36
915	Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications. Cancers, 2021, 13, 4641.	1.7	10
916	MicroRNA-495/TGF- β 2/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochemical Pharmacology, 2021, 192, 114692.	2.0	12
917	The role of glycometabolic plasticity in cancer. Pathology Research and Practice, 2021, 226, 153595.	1.0	13
918	Osteopontin Expression in Thyroid Cancer: Deciphering EMT-Related Molecular Mechanisms. Biomedicines, 2021, 9, 1372.	1.4	5

#	ARTICLE	IF	CITATIONS
919	MiR-128-3p suppresses tumor proliferation and metastasis via targeting CDC6 in hepatocellular carcinoma cells. <i>Tissue and Cell</i> , 2021, 72, 101534.	1.0	11
920	Intravital microscopy to illuminate cell state plasticity during metastasis. <i>Current Opinion in Cell Biology</i> , 2021, 72, 28-35.	2.6	9
921	Cancer cell states and emergent properties of the dynamic tumor system. <i>Genome Research</i> , 2021, 31, 1719-1727.	2.4	12
922	Engineered ECM models: Opportunities to advance understanding of tumor heterogeneity. <i>Current Opinion in Cell Biology</i> , 2021, 72, 1-9.	2.6	16
923	Senescent cells in cancer therapy: why and how to remove them. <i>Cancer Letters</i> , 2021, 520, 68-79.	3.2	18
924	Lactic acid in tumor invasion. <i>Clinica Chimica Acta</i> , 2021, 522, 61-69.	0.5	23
925	The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics. , 2021, 227, 107881.		27
926	Identification of biomarkers for acute leukemia via machine learning-based stemness index. <i>Gene</i> , 2021, 804, 145903.	1.0	7
927	Butein induces intrinsic pathway of apoptosis, vimentin proteolysis, and inhibition of cancer stem cell population in a human papillary thyroid cancer cell line. <i>Toxicology in Vitro</i> , 2021, 77, 105244.	1.1	5
928	The high expression of miR-31 in lung adenocarcinoma inhibits the malignancy of lung adenocarcinoma tumor stem cells. <i>Biochemistry and Biophysics Reports</i> , 2021, 28, 101122.	0.7	3
929	Drug resistance in colorectal cancer: An epigenetic overview. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188623.	3.3	30
930	Plant-derived small molecule inhibitors as modulators of EMT pathway in cancer chemoprevention. <i>Studies in Natural Products Chemistry</i> , 2021, , 45-65.	0.8	0
931	Typical Tumor Immune Microenvironment Status Determine Prognosis in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
932	PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas. <i>Oncogenesis</i> , 2021, 10, 12.	2.1	38
933	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
934	The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. <i>Theranostics</i> , 2021, 11, 5847-5862.	4.6	31
935	The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 1570-1579.	3.2	12
936	SNX-2112 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Non-Small Cell Lung Cancer by Downregulating Epithelial-Mesenchymal Transition via the Wnt/ β 2-Catenin Signaling Pathway. <i>Journal of Cancer</i> , 2021, 12, 5825-5837.	1.2	8

#	ARTICLE	IF	CITATIONS
937	A multifunctional nanodiamond-based nanoplatform for the enhanced mild-temperature photothermal/chemo combination therapy of triple negative breast cancer <i>via</i> an autophagy regulation strategy. <i>Nanoscale</i> , 2021, 13, 13375-13389.	2.8	26
938	MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 84.	1.3	15
939	NEDD9 promotes cancer stemness by recruiting myeloid-derived suppressor cells & CXCL8 in esophageal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 705-720.	1.4	12
940	Recent advances in molecular mechanisms of anticancer natural products that target mitochondrial bioenergetics. <i>Studies in Natural Products Chemistry</i> , 2021, 71, 1-43.	0.8	4
941	Stiffening of DU145 prostate cancer cells driven by actin filaments \leftrightarrow microtubule crosstalk conferring resistance to microtubule-targeting drugs. <i>Nanoscale</i> , 2021, 13, 6212-6226.	2.8	21
942	Isolation and Identification of EMT Subtypes. <i>Methods in Molecular Biology</i> , 2021, 2179, 315-326.	0.4	3
943	Introduction to the Acquisition of Resistance to Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 1-33.	0.1	2
944	The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1219, 311-333.	0.8	6
945	Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 11-34.	0.8	12
946	Par-4 mediated Smad4 induction in PDAC cells restores canonical TGF- β / Smad4 axis driving the cells towards lethal EMT. <i>European Journal of Cell Biology</i> , 2020, 99, 151076.	1.6	15
947	Reversal of EGFR inhibitors TM resistance by co-delivering EGFR and integrin α β 3 inhibitors with nanoparticles in non-small cell lung cancer. <i>Bioscience Reports</i> , 2019, 39, .	1.1	11
948	PI3K in stemness regulation: from development to cancer. <i>Biochemical Society Transactions</i> , 2020, 48, 301-315.	1.6	42
949	Induction of extrinsic and intrinsic apoptosis in cervical cancer cells by <i>Momordica dioica</i> mediated gold nanoparticles. <i>IET Nanobiotechnology</i> , 2020, 14, 172-179.	1.9	9
958	Tumor-associated macrophages secrete CCL2 chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. <i>Cancer Science</i> , 2020, 111, 47-58.	1.7	141
959	Sensitive and easy screening for circulating tumor cells by flow cytometry. <i>JCI Insight</i> , 2019, 4, .	2.3	31
960	Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1384-1396.	3.9	99
961	Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 4413-4428.	3.9	44
962	The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. <i>Blood</i> , 2020, 136, 596-609.	0.6	30

#	ARTICLE	IF	CITATIONS
963	Next-Generation Sequencing Analysis of mRNA Profile in Cisplatin-Resistant Gastric Cancer Cell Line SGC7901. <i>Medical Science Monitor</i> , 2019, 25, 2386-2396.	0.5	8
964	Inhibitor of Differentiation 1 (ID1) Facilitates the Efficacy of Sorafenib in Non-Small Cell Lung Cancer Cells through Suppressing Epithelial to Mesenchymal Transition. <i>Medical Science Monitor</i> , 2020, 26, e922148.	0.5	1
965	GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer. <i>PLoS ONE</i> , 2017, 12, e0182696.	1.1	18
966	The Role of Hippo Pathway in Cancer Stem Cell Biology. <i>Molecules and Cells</i> , 2018, 41, 83-92.	1.0	140
967	Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. <i>Cellular and Molecular Biology</i> , 2020, 66, 81.	0.3	7
968	Tumor suppressive effects of the pleiotropically acting miR-195 in colorectal cancer cells. <i>EXCLI Journal</i> , 2019, 18, 243-252.	0.5	8
969	Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients. <i>Aging</i> , 2019, 11, 2874-2888.	1.4	25
970	Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins. <i>Aging</i> , 2019, 11, 11770-11792.	1.4	25
971	UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. <i>Aging</i> , 2020, 12, 10275-10289.	1.4	23
972	HOXC10 promotes tumour metastasis by regulating the EMT-related gene Slug in ovarian cancer. <i>Aging</i> , 2020, 12, 19375-19398.	1.4	15
973	Drug-selected population in melanoma A2058 cells as melanoma stem-like cells retained angiogenic features – the potential roles of heparan-sulfate binding ANGPTL4 protein. <i>Aging</i> , 2020, 12, 22700-22718.	1.4	2
974	Deregulated expression of microRNA-200b/c and SUZ12, a Polycomb repressive complex 2 subunit, in chemoresistant colorectal cancer cells. <i>Genes and Cancer</i> , 2017, 8, 673-681.	0.6	10
975	Novel strategies to target chemoresistant triple-negative breast cancer. <i>Genes and Cancer</i> , 2020, 11, 95-105.	0.6	3
976	Klf4 reduces stemness phenotype, triggers mesenchymal-epithelial transition (MET)-like molecular changes, and prevents tumor progression in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2017, 8, 93924-93941.	0.8	21
977	DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition. <i>Oncotarget</i> , 2017, 8, 94028-94039.	0.8	37
978	A mechanism-based computational model to capture the interconnections among epithelial-mesenchymal transition, cancer stem cells and Notch-Jagged signaling. <i>Oncotarget</i> , 2018, 9, 29906-29920.	0.8	67
979	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	11
980	Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 297-312.	0.9	9

#	ARTICLE	IF	CITATIONS
981	Drug resistance and combating drug resistance in cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 141-160.	0.9	388
982	The role of histone lysine demethylases in cancer cellsâ€™ resistance to tyrosine kinase inhibitors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 326-334.	0.9	2
983	Decoding cancerâ€™s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
984	Eradicating the Roots: Advanced Therapeutic Approaches Targeting Breast Cancer Stem Cells. <i>Current Pharmaceutical Design</i> , 2020, 26, 2009-2021.	0.9	4
985	Cancer Stem Cells Equipped with Powerful Hedgehog Signaling and Better Epigenetic Memory: Avenues to Look for Cancer Therapeutics. <i>Current Cancer Drug Targets</i> , 2019, 19, 877-884.	0.8	5
986	Angiotensin Inhibition, TGF- β 2 and EMT in Cancer. <i>Cancers</i> , 2020, 12, 2785.	1.7	28
987	Targeting Oncoimmune Drivers of Cancer Metastasis. <i>Cancers</i> , 2021, 13, 554.	1.7	15
988	SIX1 ve Kanser Kâ€™r H β 4cre BelirteÅšlerinin Hepatoselluler Karsinomada Kapsamlı± Analizi. <i>Celal Bayar Âœniversitesi SaÅšlık Bilimleri Enstitüsü Dergisi</i> , 0, , .	0.1	1
989	Assessment of biochemical recurrence of prostate cancer (Review). <i>International Journal of Oncology</i> , 2019, 55, 1194-1212.	1.4	14
990	Clinical importance of long non-coding RNA LINC00460 expression in EGFRâ€™mutant lung adenocarcinoma. <i>International Journal of Oncology</i> , 2020, 56, 243-257.	1.4	19
991	Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatinâ€™resistant non-small cell lung cancer. <i>International Journal of Oncology</i> , 2020, 56, 1083-1092.	1.4	8
992	Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis. <i>Oncology Letters</i> , 2019, 18, 5428-5436.	0.8	16
993	The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation. <i>Oncology Letters</i> , 2020, 19, 211-220.	0.8	21
994	Hispidulin modulates epithelialâ€™mesenchymal transition in breast cancer cells. <i>Oncology Letters</i> , 2020, 21, 155.	0.8	9
995	B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 224.	0.8	8
996	Pan-cancer systematic identification of lncRNAs associated with cancer prognosis. <i>PeerJ</i> , 2020, 8, e8797.	0.9	3
997	Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts. <i>Theranostics</i> , 2021, 11, 9667-9686.	4.6	16
998	RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA. <i>Oncogene</i> , 2021, 40, 6430-6442.	2.6	10

#	ARTICLE	IF	CITATIONS
999	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. <i>Journal of Molecular Medicine</i> , 2021, 99, 1691-1710.	1.7	40
1000	Arsenic Trioxide Promotes Tumor Progression by Inducing the Formation of PGCCs and Embryonic Hemoglobin in Colon Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 720814.	1.3	14
1001	Epithelial to Mesenchymal Transition: A Challenging Playground for Translational Research. Current Models and Focus on TWIST1 Relevance and Gastrointestinal Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11469.	1.8	9
1002	A highly annotated database of genes associated with platinum resistance in cancer. <i>Oncogene</i> , 2021, 40, 6395-6405.	2.6	41
1003	Anti-cancer adjuvant drug screening via epithelial-mesenchymal transition-related aptamer probe. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 6951-6962.	1.9	1
1004	An Integrated View of Virus-Triggered Cellular Plasticity Using Boolean Networks. <i>Cells</i> , 2021, 10, 2863.	1.8	1
1005	Pirfenidone Reduces Epithelial-Mesenchymal Transition and Spheroid Formation in Breast Carcinoma through Targeting Cancer-Associated Fibroblasts (CAFs). <i>Cancers</i> , 2021, 13, 5118.	1.7	12
1007	Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells. <i>Veterinary and Comparative Oncology</i> , 2022, 20, 313-323.	0.8	3
1008	CL-ACP: a parallel combination of CNN and LSTM anticancer peptide recognition model. <i>BMC Bioinformatics</i> , 2021, 22, 512.	1.2	10
1009	Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade. <i>Cell Death and Disease</i> , 2021, 12, 993.	2.7	23
1010	UCH-L1 and UCH-L3 regulate the cancer stem cell-like properties through PI3K/Akt signaling pathway in prostate cancer cells. <i>Animal Cells and Systems</i> , 2021, 25, 312-322.	0.8	11
1011	Signal processing capacity of the cellular sensory machinery regulates the accuracy of chemotaxis under complex cues. <i>IScience</i> , 2021, 24, 103242.	1.9	7
1012	Luteolin attenuates cancer cell stemness in PTX-resistant oesophageal cancer cells through mediating SOX2 protein stability. <i>Pharmacological Research</i> , 2021, 174, 105939.	3.1	20
1013	The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade During HER2-Positive Breast Cancer Progression. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1017	Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. <i>Oncoscience</i> , 2018, 5, 214-215.	0.9	0
1020	Targeting Cancer from a Structural Biology Perspective. , 2019, , 295-320.		0
1021	Acquisition of tumor marker candidate proteins using two-dimensional gel electrophoresis. <i>Denki Eido</i> , 2019, 63, 7-9.	0.0	0
1026	HSP27 promotes epithelial-mesenchymal transition through activation of the β -catenin/MMP3 pathway in pancreatic ductal adenocarcinoma cells. <i>Translational Cancer Research</i> , 2019, 8, 1268-1278.	0.4	3

#	ARTICLE	IF	CITATIONS
1027	Quest of EMT and CSC. Journal of Clinical and Medical Research, 0, , .	0.0	0
1032	Single-Cell Transcriptome Sequencing Using Microfluidics. , 2020, , 1-25.		0
1033	CELL SURFACE MOLECULAR MARKERS FOR IDENTIFICATION OF CANCER STEM CELL POPULATIONS (SYSTEMATIC REVIEW). Voprosy Onkologii, 2020, 66, 336-345.	0.1	0
1035	Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery. Seminars in Cancer Biology, 2022, 80, 195-204.	4.3	13
1036	High expression of PSF1 promotes drug resistance and cell cycle transit in leukemia cells. Cancer Science, 2020, 111, 2400-2412.	1.7	6
1038	Mitochondria of transformed cell as a target of antitumor influence. IssledovaniĀ I Praktika V Medicine, 2020, 7, 92-108.	0.1	3
1039	Primary tumor cell cultures: Ćurrent methods of obtaining and subcultivation. South Russian Journal of Cancer, 2020, 1, 36-49.	0.1	4
1040	Epithelial-Mesenchymal Transition in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2020, 63, 397-402.	0.0	0
1041	Single-Cell Transcriptome Sequencing Using Microfluidics. , 2022, , 607-630.		0
1042	Epithelial-to-Mesenchymal Transition-Derived Heterogeneity in Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 5355.	1.7	15
1043	EGFR is a pivotal player of the E2/ERĀ ² Ā-mediated functional properties, aggressiveness, and stemness in tripleĀ-negative breast cancer cells. FEBS Journal, 2022, 289, 1552-1574.	2.2	13
1044	FBXL10 promotes EMT and metastasis of breast cancer cells via regulating the acetylation and transcriptional activity of SNAI1. Cell Death Discovery, 2021, 7, 328.	2.0	9
1046	A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer. Cancers, 2021, 13, 4.	1.7	9
1048	Evaluation of early post-natal pig mammary gland development and human breast cancer gene expression. Developmental Biology, 2022, 481, 95-103.	0.9	4
1049	A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors. Translational Oncology, 2022, 15, 101257.	1.7	2
1051	Cancer Stem Cells. , 2020, , 15-34.		0
1053	Introduction to Cancer Stem Cells. , 2020, , 1-13.		0
1055	Relevance of Autophagy in Cancer Stem Cell and Therapeutic. , 2020, , 203-222.		0

#	ARTICLE	IF	CITATIONS
1056	The prognostic value of GSK3 β , eEF2K, and Atg7 expressions in triple-negative breast cancers: a clinicopathological study. <i>Egyptian Journal of Pathology</i> , 2020, 40, 217.	0.0	0
1057	Vitamin D Compounds and Cancer Stem Cells in Cancer Prevention. , 2020, , 143-159.		0
1060	Lipid raft α disrupting miltefosine preferentially induces the death of colorectal cancer stem α like cells. <i>Clinical and Translational Medicine</i> , 2021, 11, e552.	1.7	15
1062	ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT). <i>Scientific Reports</i> , 2021, 11, 21984.	1.6	8
1063	Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. <i>Cancers</i> , 2021, 13, 5532.	1.7	25
1064	Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2018, 8, 154-164.	1.4	8
1065	Dysregulated ENPP1 increases the malignancy of human lung cancer by inducing epithelial-mesenchymal transition phenotypes and stem cell features. <i>American Journal of Cancer Research</i> , 2019, 9, 134-144.	1.4	6
1066	Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 800-815.	1.4	17
1067	Targeting E-cadherin expression with small molecules for digestive cancer treatment. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 3932-3944.	0.0	19
1068	MicroRNA-940 inhibits epithelial-mesenchymal transition of glioma cells via targeting ZEB2. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 7351-7363.	0.0	9
1069	Expression of vimentin and Oct-4 in gallbladder adenocarcinoma and their relationship with vasculogenic mimicry and their clinical significance. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 3618-3627.	0.5	1
1070	Stem Cells in Ovarian Cancer and Potential Therapies. <i>Proceedings of Stem Cell Research & Oncogenesis</i> , 2020, 8, .	1.0	3
1071	Eradication of CSCs: the roadmap for curing cancer. <i>Oncoscience</i> , 2020, 7, 70-72.	0.9	0
1072	ZNF451 stabilizes TWIST2 through SUMOylation and promotes epithelial-mesenchymal transition. <i>American Journal of Cancer Research</i> , 2021, 11, 898-915.	1.4	2
1073	Effect of Menadione and Combination of Gemcitabine and Cisplatin α on Cancer Stem Cells in Human Non-small Cell Lung Cancer (NSCLC) Cell Line A549. <i>Iranian Journal of Pharmaceutical Research</i> , 2021, 20, 105-117.	0.3	3
1074	DCLK1 Inhibition Sensitizes Colorectal Cancer Cells to Radiation Treatment. <i>International Journal of Molecular and Cellular Medicine</i> , 2021, 10, 23-33.	1.1	3
1075	ZNF217: the cerberus who fails to guard the gateway to lethal malignancy. <i>American Journal of Cancer Research</i> , 2021, 11, 3378-3405.	1.4	0
1076	Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"? <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 254-260.	0.4	0

#	ARTICLE	IF	CITATIONS
1077	Targeting the metabolism of cancer stem cells by energy disruptor molecules. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103545.	2.0	11
1078	Anti-Cancer Activity Profiling of Chemotherapeutic Agents in 3D Co-Cultures of Pancreatic Tumor Spheroids with Cancer-Associated Fibroblasts and Macrophages. <i>Cancers</i> , 2021, 13, 5955.	1.7	12
1079	The Hippo Signaling Pathway: The Trader of Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 772134.	1.3	13
1080	Cluster size distribution of cells disseminating from a primary tumor. <i>PLoS Computational Biology</i> , 2021, 17, e1009011.	1.5	5
1081	B7 family member H4 induces epithelial-mesenchymal transition and promotes the proliferation, migration and invasion of colorectal cancer cells. <i>Bioengineered</i> , 2022, 13, 107-118.	1.4	5
1082	TGF β -induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. <i>Hepatology Communications</i> , 2022, 6, 1157-1171.	2.0	9
1083	Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival. <i>British Journal of Cancer</i> , 2022, 126, 409-418.	2.9	5
1084	Cell Cycle Regulation and DNA Damage Response Networks in Diffuse- and Intestinal-Type Gastric Cancer. <i>Cancers</i> , 2021, 13, 5786.	1.7	6
1085	The IVF-generated human embryonic microenvironment reverses progesterin resistance in endometrial cancer cells by inducing cancer stem cell differentiation. <i>Cancer Letters</i> , 2022, 526, 311-321.	3.2	7
1086	Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 768918.	1.3	24
1087	Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics. <i>Genes</i> , 2021, 12, 1900.	1.0	22
1088	Parathyroid Hormone-Related Protein Inhibition Blocks Triple-Negative Breast Cancer Expansion in Bone Through Epithelial to Mesenchymal Transition Reversal. <i>JBMR Plus</i> , 2022, 6, .	1.3	2
1089	Detection of cancer stem cells by EMT-specific biomarker-based peptide ligands. <i>Scientific Reports</i> , 2021, 11, 22430.	1.6	8
1090	Epithelial-Mesenchymal Transition Induces GSDME Transcriptional Activation for Inflammatory Pyroptosis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 781365.	1.8	8
1091	Upregulation of homeobox D10 expression suppresses invasion and migration of clear cell renal cell carcinoma through targeting of E-cadherin. <i>Molecular Biology Reports</i> , 2021, , 1.	1.0	1
1092	Tumour Microenvironment Stress Promotes the Development of Drug Resistance. <i>Antioxidants</i> , 2021, 10, 1801.	2.2	29
1093	Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12438.	1.8	15
1094	Salinomycin as a potent anticancer stem cell agent: State of the art and future directions. <i>Medicinal Research Reviews</i> , 2022, 42, 1037-1063.	5.0	33

#	ARTICLE	IF	CITATIONS
1095	Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5956.	1.7	13
1096	Distinct contributions of partial and full EMT to breast cancer malignancy. <i>Developmental Cell</i> , 2021, 56, 3203-3221.e11.	3.1	160
1097	The Biophysics of Cancer: Emerging Insights from Micro- and Nanoscale Tools. <i>Advanced NanoBiomed Research</i> , 2022, 2, 2100056.	1.7	9
1098	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 373-386.	1.5	7
1099	Mechanistic Insights Delineating the Role of Cholesterol in Epithelial Mesenchymal Transition and Drug Resistance in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 728325.	1.8	16
1101	Modulating undruggable targets to overcome cancer therapy resistance. <i>Drug Resistance Updates</i> , 2022, 60, 100788.	6.5	15
1102	Immune Infiltration, Cancer Stemness, and Targeted Therapy in Gastrointestinal Stromal Tumor. <i>Frontiers in Immunology</i> , 2021, 12, 691713.	2.2	3
1103	CD8 ⁺ T cell dysfunction by TOX intoxication: a protumorigenic event in the tumor microenvironment. <i>Future Oncology</i> , 2021, 17, 5129-5134.	1.1	0
1104	Tumour microenvironment: a non-negligible driver for epithelial-mesenchymal transition in colorectal cancer. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e16.	1.6	21
1105	Cancer Stem Cells and the Tumor Microenvironment in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 803974.	1.3	20
1106	Pyruvate Dehydrogenase Contributes to Drug Resistance of Lung Cancer Cells Through Epithelial Mesenchymal Transition. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 738916.	1.8	7
1107	Accentuating CircRNA-miRNA-Transcription Factors Axis: A Conundrum in Cancer Research. <i>Frontiers in Pharmacology</i> , 2021, 12, 784801.	1.6	23
1108	Aloperine inhibits colorectal cancer cell proliferation and metastasis progress via regulating miR-296-5p/STAT3 axis. <i>Tissue and Cell</i> , 2022, 74, 101706.	1.0	6
1109	The expression and function of miR-622 in a variety of tumors. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112544.	2.5	7
1110	Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. <i>Translational Oncology</i> , 2022, 17, 101317.	1.7	12
1111	Ganoderma lucidum polysaccharides inhibit in vitro tumorigenesis, cancer stem cell properties and epithelial-mesenchymal transition in oral squamous cell carcinoma. <i>Journal of Ethnopharmacology</i> , 2022, 286, 114891.	2.0	23
1112	Eradication of CSCs: the roadmap for curing cancer. <i>Oncoscience</i> , 2020, 7, 70-72.	0.9	0
1113	MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal. <i>Pancreas</i> , 2021, 50, 1260-1266.	0.5	6

#	ARTICLE	IF	CITATIONS
1114	Role of CD44 isoforms in epithelial-mesenchymal plasticity and metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 391-406.	1.7	19
1115	The Epithelial-Mesenchymal Transition at the Crossroads between Metabolism and Tumor Progression. <i>International Journal of Molecular Sciences</i> , 2022, 23, 800.	1.8	59
1116	CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1565.	1.8	7
1117	Detyrosinated α -Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 154.	1.1	7
1118	Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties. <i>Journal of Virology</i> , 2022, 96, jvi0194121.	1.5	5
1120	Reversing the Epithelial-Mesenchymal Transition in Metastatic Cancer Cells Using CD146-Targeted Black Phosphorus Nanosheets and a Mild Photothermal Treatment. <i>ACS Nano</i> , 2022, 16, 3208-3220.	7.3	11
1121	Loss of circadian gene Timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. <i>Cell Death and Differentiation</i> , 2022, 29, 1552-1568.	5.0	18
1122	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 812422.	1.8	5
1123	The role of metabolic ecosystem in cancer progression – metabolic plasticity and mTOR hyperactivity in tumor tissues. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 989-1033.	2.7	14
1124	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. <i>Drug Resistance Updates</i> , 2022, 60, 100811.	6.5	13
1125	microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1275.	1.8	12
1127	Interaction between avian leukosis virus subgroup J surface protein and doublecortin-like kinase 1 accelerates cell proliferation and epithelial-mesenchymal transition. <i>Journal of Virology</i> , 2022, , jvi0165721.	1.5	4
1128	Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 799223.	1.3	7
1129	Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF- β 2 pathway. <i>Cancer Gene Therapy</i> , 2022, 29, 1168-1180.	2.2	8
1130	Cyclophilin A regulates the apoptosis of A549 cells by stabilizing Twist1 protein. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	9
1131	Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 772770.	1.3	8
1133	Exosomal-long non-coding RNAs journey in colorectal cancer: Evil and goodness faces of key players. <i>Life Sciences</i> , 2022, 292, 120325.	2.0	47
1134	Molecular Basis of Resveratrol-Induced Resensitization of Acquired Drug-Resistant Cancer Cells. <i>Nutrients</i> , 2022, 14, 699.	1.7	16

#	ARTICLE	IF	CITATIONS
1135	Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes. <i>BioMed Research International</i> , 2022, 2022, 1-36.	0.9	3
1136	Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas. <i>Cells</i> , 2022, 11, 561.	1.8	18
1137	Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer. <i>Biomolecules</i> , 2022, 12, 284.	1.8	8
1138	TGF- β 1 induced deficiency of linc00261 promotes epithelial-to-mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3. <i>Journal of Translational Medicine</i> , 2022, 20, 75.	1.8	7
1139	FAK in Cancer: From Mechanisms to Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1726.	1.8	61
1140	Infection by High-Risk Human Papillomaviruses, Epithelial-to-Mesenchymal Transition and Squamous Pre-Malignant or Malignant Lesions of the Uterine Cervix: A Series of Chained Events?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13543.	1.8	12
1143	Extracellular ATP and Macropinocytosis: Their Interactive and Mutually Supportive Roles in Cell Growth, Drug Resistance, and EMT in Cancer. <i>Sub-Cellular Biochemistry</i> , 2022, 98, 61-83.	1.0	1
1144	Meme Kanserinde Tamoksifen Direncinde IL-6/STAT3 YolaÄ± Temelli EMT MekanizmasÄ±n Rolü. <i>Sakarya Medical Journal</i> , 0, , .	0.1	0
1145	Smurf2 suppresses the metastasis of hepatocellular carcinoma via ubiquitin degradation of Smad2. <i>Open Medicine (Poland)</i> , 2022, 17, 384-396.	0.6	2
1146	Intrinsic and Extrinsic Factors Impacting Cancer Stemness and Tumor Progression. <i>Cancers</i> , 2022, 14, 970.	1.7	19
1147	METTL3 promotes oxaliplatin resistance of gastric cancer CD133+ stem cells by promoting PARP1 mRNA stability. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 135.	2.4	47
1148	Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence. <i>Cancers</i> , 2022, 14, 976.	1.7	46
1149	Antitumor Effects of Natural Bioactive Ursolic Acid in Embryonic Cancer Stem Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	3
1150	The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype. <i>Frontiers in Oncology</i> , 2022, 12, 817971.	1.3	8
1152	The Bright and the Dark Side of TGF- β 2 Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications. <i>Cancers</i> , 2022, 14, 940.	1.7	16
1153	Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy. <i>Cancers</i> , 2022, 14, 1165.	1.7	6
1154	Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization. <i>Cell Death and Disease</i> , 2022, 13, 166.	2.7	3
1155	Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer. <i>Genes and Diseases</i> , 2022, 9, 868-888.	1.5	1

#	ARTICLE	IF	CITATIONS
1156	The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting. <i>Cancers</i> , 2022, 14, 1480.	1.7	17
1157	The Role of Tumor Stem Cell Exosomes in Cancer Invasion and Metastasis. <i>Frontiers in Oncology</i> , 2022, 12, 836548.	1.3	17
1158	Assessment of the targeted effect of Sijunzi decoction on the colorectal cancer microenvironment via the ESTIMATE algorithm. <i>PLoS ONE</i> , 2022, 17, e0264720.	1.1	4
1160	The Impact of Epithelial–Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 467.	0.8	5
1161	Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 840198.	2.2	9
1162	Understanding autophagy role in cancer stem cell development. <i>Molecular Biology Reports</i> , 2022, 49, 6741-6751.	1.0	5
1163	Exosomes Regulate the Epithelial–Mesenchymal Transition in Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 864980.	1.3	23
1164	Biophysics Role and Biomimetic Culture Systems of ECM Stiffness in Cancer EMT. <i>Global Challenges</i> , 2022, 6, .	1.8	5
1165	ZEB1 transcription factor promotes immune escape in melanoma. , 2022, 10, e003484.		35
1166	Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 873116.	2.2	12
1167	Roles of RNA-binding proteins in immune diseases and cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 310-324.	4.3	14
1168	Inhibition of GLI-Mediated Transcription by Cyclic Pyrrole-Imidazole Polyamide in Cancer Stem Cells. <i>Bulletin of the Chemical Society of Japan</i> , 2022, 95, 693-699.	2.0	10
1169	Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. <i>Medicinal Research Reviews</i> , 2022, 42, 1607-1660.	5.0	20
1171	Analysis of Stemness and Prognosis of Subtypes in Breast Cancer Using the Transcriptome Sequencing Data. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	1
1172	Fibrous stroma: Driver and passenger in cancer development. <i>Science Signaling</i> , 2022, 15, eabg3449.	1.6	15
1173	Identification of Prognosis Biomarkers for High-Grade Serous Ovarian Cancer Based on Stemness. <i>Frontiers in Genetics</i> , 2022, 13, 861954.	1.1	5
1174	Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. <i>Trends in Cancer</i> , 2022, 8, 456-466.	3.8	6
1175	Comprehensive Atlas of Circulating Rare Cells Detected by SE-iFISH and Image Scanning Platform in Patients With Various Diseases. <i>Frontiers in Oncology</i> , 2022, 12, 821454.	1.3	6

#	ARTICLE	IF	CITATIONS
1176	Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression. <i>Molecular Cancer</i> , 2022, 21, 74.	7.9	69
1177	Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1010-1019.	1.9	9
1178	Novel Stemness-Related Gene Signature Predicting Prognosis and Indicating a Different Immune Microenvironment in HNSCC. <i>Frontiers in Genetics</i> , 2022, 13, 822115.	1.1	4
1179	Combating Cancer Stem-Like Cell-Derived Resistance to Anticancer Protein by Liposome-Mediated Acclimatization Strategy. <i>Nano Letters</i> , 2022, 22, 2419-2428.	4.5	12
1180	An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. <i>BMC Cancer</i> , 2022, 22, 256.	1.1	4
1181	Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3263-3280.	5.7	11
1182	Effects of Curcumin-mediated photodynamic therapy on autophagy and epithelial-mesenchymal transition of lung cancer cells. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 38, 102849.	1.3	10
1183	Epithelialâ€“Mesenchymal Plasticity in Tumor Immune Evasion. <i>Cancer Research</i> , 2022, 82, 2329-2343.	0.4	23
1184	Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 122.	3.5	20
1185	3D microgels to quantify tumor cell properties and therapy response dynamics. <i>Biomaterials</i> , 2022, 283, 121417.	5.7	11
1186	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. <i>Translational Oncology</i> , 2022, 18, 101367.	1.7	10
1187	Integrated Bioinformatics Analysis Identifies a New Stemness Index-Related Survival Model for Prognostic Prediction in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 860268.	1.1	7
1188	Cancer: More than a geneticistâ€™s Pandoraâ€™s box. <i>Journal of Biosciences</i> , 2022, 47, .	0.5	2
1189	B7-H4 expression promotes non-small cell lung cancer progression via AMPK/mTOR signaling. <i>Experimental and Molecular Pathology</i> , 2022, 125, 104755.	0.9	5
1190	Ubiquitination and deubiquitination in the regulation of epithelial-mesenchymal transition in cancer: Shifting gears at the molecular level. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119261.	1.9	9
1191	Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6235.	1.7	2
1192	Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Autophagy Inhibition. <i>Cancers</i> , 2021, 13, 6124.	1.7	7
1193	Eâ€œcadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. <i>Molecular Oncology</i> , 2022, 16, 2312-2329.	2.1	4

#	ARTICLE	IF	CITATIONS
1194	The Autophagic Route of E-Cadherin and Cell Adhesion Molecules in Cancer Progression. <i>Cancers</i> , 2021, 13, 6328.	1.7	10
1195	TEAD4 overexpression suppresses thyroid cancer progression and metastasis in vitro by modulating Wnt signaling. <i>Journal of Biosciences</i> , 2022, 47, 1.	0.5	3
1196	Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma. <i>Cancers</i> , 2021, 13, 6100.	1.7	4
1197	NOX4: a potential therapeutic target for pancreatic cancer and its mechanism. <i>Journal of Translational Medicine</i> , 2021, 19, 515.	1.8	15
1198	AEBP1 Is One of the Epithelial-Mesenchymal Transition Regulatory Genes in Colon Adenocarcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-16.	0.9	6
1199	Rethinking the chemokine cascade in brain metastasis: Preventive and therapeutic implications. <i>Seminars in Cancer Biology</i> , 2022, 86, 914-930.	4.3	7
1200	Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective. <i>Pharmaceutics</i> , 2021, 13, 2116.	2.0	16
1201	Insights of RKIP-Derived Suppression of Prostate Cancer. <i>Cancers</i> , 2021, 13, 6388.	1.7	6
1202	Cooperative interaction between ER α and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis. <i>Nature Communications</i> , 2022, 13, 2104.	5.8	28
1203	A Novel Epithelial-Mesenchymal Transition Gene Signature Correlated With Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 863750.	1.6	6
1204	Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. <i>Pharmaceutics</i> , 2022, 14, 866.	2.0	17
1205	Epithelial-mesenchymal transition and cancer stem cells: A route to acquired cisplatin resistance through epigenetics in HNSCC. <i>Oral Diseases</i> , 2023, 29, 1991-2005.	1.5	8
1206	H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity. <i>Oncogene</i> , 2022, 41, 2958-2972.	2.6	8
1207	The paradigm of drug resistance in cancer: an epigenetic perspective. <i>Bioscience Reports</i> , 2022, 42, .	1.1	21
1208	Construction of multifunctional lanthanide-based nanoparticles Ba ₂ LuF ₇ : Yb/Er/Ho for in vivo dual-modal tumor imaging. <i>Optical Materials</i> , 2022, 128, 112369.	1.7	4
1235	Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells. <i>FEBS Open Bio</i> , 2022, 12, 1353-1364.	1.0	5
1236	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 762-774.	1.9	9
1238	Protruding structures with high expression of LGR5 are formed during regrowth phase after chemo-treatment in xenograft model of colorectal adenocarcinoma. <i>Histology and Histopathology</i> , 2021, , 18374.	0.5	0

#	ARTICLE	IF	CITATIONS
1240	Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research.. International Journal of Molecular and Cellular Medicine, 2021, 10, 163-181.	1.1	2
1241	EGFR inhibition reverses epithelial-mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Oncology Reports, 2022, 47, .	1.2	7
1242	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. American Journal of Cancer Research, 2022, 12, 337-354.	1.4	0
1243	3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma. In Vivo, 2022, 36, 1155-1167.	0.6	7
1245	Pancreatic cancer cell-derived exosomes induce epithelial-mesenchymal transition in human pancreatic cancer cells themselves partially via transforming growth factor β 1. Medical Molecular Morphology, 2022, 55, 227-235.	0.4	8
1246	The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer. Cancers, 2022, 14, 2101.	1.7	11
1247	Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. British Journal of Cancer, 2022, 127, 800-810.	2.9	38
1248	EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures. Cancers, 2022, 14, 2176.	1.7	5
1249	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy. Frontiers in Oncology, 2022, 12, 859455.	1.3	2
1250	Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. Frontiers in Oncology, 2022, 12, 818437.	1.3	7
1251	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 874091.	1.3	2
1252	Divergent Roles of Mitochondria Dynamics in Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 2155.	1.7	7
1253	Transforming Growth Factor Beta Promotes the Expansion of Cancer Stem Cells <i>via</i> S1PR3 by Ligand-Independent Notch Activation. Biological and Pharmaceutical Bulletin, 2022, 45, 649-658.	0.6	2
1254	A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition. Cancers, 2022, 14, 2311.	1.7	7
1255	LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing <i>LOXL2</i> -induced epithelial-mesenchymal transition (EMT). Cell Cycle, 2022, 21, 1827-1841.	1.3	5
1256	Advances in the Study of CircRNAs in Tumor Drug Resistance. Frontiers in Oncology, 2022, 12, .	1.3	5
1257	Role of the Pro-Inflammatory Tumor Microenvironment in Extracellular Vesicle-Mediated Transfer of Therapy Resistance. Frontiers in Oncology, 2022, 12, .	1.3	7
1258	Nanomaterial-mediated ablation therapy for cancer stem cells. Matter, 2022, 5, 1367-1390.	5.0	12

#	ARTICLE	IF	CITATIONS
1259	Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2022, 13, 181.	2.4	33
1260	Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-22.	1.9	4
1261	Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition. <i>Molecular Biology Reports</i> , 2022, 49, 4307-4319.	1.0	3
1262	TGF- β 2-Induced FLRT3 Attenuation Is Essential for Cancer-Associated Fibroblast-Mediated Epithelial-Mesenchymal Transition in Colorectal Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1247-1259.	1.5	16
1263	The Antileukemic and Anti-Prostatic Effect of Aeroplysinin-1 Is Mediated through ROS-Induced Apoptosis via NOX Activation and Inhibition of HIF-1 α Activity. <i>Life</i> , 2022, 12, 687.	1.1	12
1264	Plasma membrane phosphatidylinositol (4,5)-bisphosphate is critical for determination of epithelial characteristics. <i>Nature Communications</i> , 2022, 13, 2347.	5.8	9
1265	Tumour Stem Cells in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5058.	1.8	14
1266	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	1.7	15
1267	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	2.3	3
1268	OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF- β 2 type I receptor. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 126.	7.1	15
1269	Drug repurposing: An emerging strategy in alleviating skin cancer. <i>European Journal of Pharmacology</i> , 2022, 926, 175031.	1.7	5
1270	TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non-Small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
1271	PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF- κ B, Cancer Stem Cells, and Targets Glioblastoma <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1273-1284.	1.9	9
1272	Iron-based and BRD4-downregulated strategy for amplified ferroptosis based on pH-sensitive/NIR-II-boosted nano-matchbox. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 863-878.	5.7	6
1273	Exosomes and their roles in the chemoresistance of pancreatic cancer. <i>Cancer Medicine</i> , 2022, 11, 4979-4988.	1.3	11
1274	Cancer stem-like cells contribute to paclitaxel resistance in esophageal squamous cell carcinoma.. <i>International Journal of Clinical and Experimental Pathology</i> , 2022, 15, 183-190.	0.5	0
1275	Tumor Necrosis Factor β : Taking a Personalized Road in Cancer Therapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	12
1276	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2613.	1.7	8

#	ARTICLE	IF	CITATIONS
1277	Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase. <i>British Journal of Cancer</i> , 2022, 127, 661-674.	2.9	12
1278	Cancer Stem Cells: The Greatest Menace in Conquering Cancer Management. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1279	A neutrophil-biomimic platform for eradicating metastatic breast cancer stem-like cells by redox microenvironment modulation and hypoxia-triggered differentiation therapy. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 298-314.	5.7	12
1280	Epithelialâ€mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. <i>MedComm</i> , 2022, 3, .	3.1	43
1281	FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 2689-2702.	1.4	13
1283	Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelialâ€Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1284	CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1285	A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic review). <i>Discover Oncology</i> , 2022, 13, .	0.8	7
1286	Characteristics of the cancer stem cell niche and therapeutic strategies. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	43
1287	Integrative Analysis Revealed Stemness Features and a Novel Stemness-Related Classification in Colorectal Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
1288	Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
1289	Molecular markers in cancer. <i>Clinica Chimica Acta</i> , 2022, 532, 95-114.	0.5	5
1290	Interaction of crown ethers with the ABCG2 transporter and their implication for multidrug resistance reversal. <i>Histochemistry and Cell Biology</i> , 0, , .	0.8	3
1291	Long Noncoding RNA and Circular RNA: Two Rising Stars in Regulating Epithelial-Mesenchymal Transition of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1292	The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	15
1293	YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer. <i>EBioMedicine</i> , 2022, 81, 104092.	2.7	3
1296	Microenvironmental regulation of tumor initiation and development. <i>Scientia Sinica Vitae</i> , 2022, 52, 1377-1390.	0.1	1
1297	Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning. <i>Cancer Discovery</i> , 2022, 12, 1847-1859.	7.7	26

#	ARTICLE	IF	CITATIONS
1298	Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1299	A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 906-917.	1.9	10
1300	MCRS1 Expression Regulates Tumor Activity and Affects Survival Probability of Patients with Gastric Cancer. <i>Diagnostics</i> , 2022, 12, 1502.	1.3	0
1301	CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma. <i>Aging</i> , 2022, 14, 4673-4698.	1.4	6
1302	Gene expression profile of epithelial-mesenchymal transition in tumors of patients with nscl: the influence of COPD. <i>ERJ Open Research</i> , 0, , 00105-2022.	1.1	1
1303	Liquid Biopsy: How to Embrace Perfection?. , 2022, 9, 54-56, 59.		0
1304	STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. <i>Pharmacological Research</i> , 2022, 182, 106311.	3.1	51
1305	EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization. <i>Oncogene</i> , 2022, 41, 3611-3624.	2.6	6
1306	Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy. <i>ACS Omega</i> , 2022, 7, 22743-22753.	1.6	8
1307	The overall process of metastasis: From initiation to a new tumor. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188750.	3.3	8
1308	Therapeutic Targeting of Glutamate Dehydrogenase 1 that Links Metabolic Reprogramming and Snail-Mediated Epithelial-Mesenchymal Transition in Drug-Resistant Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1309	Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 794-813.	0.9	2
1311	Formoxanthone C Inhibits Malignant Tumor Phenotypes of Human A549 Multidrug Resistant-cancer Cells through Signal Transducer and Activator of Transcription 1-Histone Deacetylase 4 Signaling. <i>Journal of Cancer Prevention</i> , 2022, 27, 112-121.	0.8	1
1312	The Role of microRNAs in Multidrug Resistance of Glioblastoma. <i>Cancers</i> , 2022, 14, 3217.	1.7	11
1314	Targeting Wnt/ β -Catenin Signaling by TET1/FOXO4 Inhibits Metastatic Spreading and Self-Renewal of Cancer Stem Cells in Gastric Cancer. <i>Cancers</i> , 2022, 14, 3232.	1.7	8
1315	The epithelial-to-mesenchymal transition in cancer: pathogenetic features. <i>Innovative Medicine of Kuban</i> , 2022, , 85-92.	0.0	0
1316	Stem Cell Models for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7055.	1.8	7
1317	Ubiquitin-Specific Protease 6 n-Terminal-like Protein (USP6NL) and the Epidermal Growth Factor Receptor (EGFR) Signaling Axis Regulates Ubiquitin-Mediated DNA Repair and Temozolomide-Resistance in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1531.	1.4	3

#	ARTICLE	IF	CITATIONS
1318	PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma. <i>Oncogene</i> , 2022, 41, 4003-4017.	2.6	20
1319	Lipocalin-2 inhibits pancreatic cancer stemness via the AKT/c-Jun pathway. <i>Human Cell</i> , 2022, 35, 1475-1486.	1.2	3
1320	Evodiamine inhibits stemness and metastasis by altering the SOX9 β -catenin axis in non-small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1454-1466.	1.2	5
1321	Tumor microenvironment involvement in colorectal cancer progression via Wnt/ β -catenin pathway: Providing understanding of the complex mechanisms of chemoresistance. <i>World Journal of Gastroenterology</i> , 2022, 28, 3027-3046.	1.4	8
1322	Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1323	Study of lead-induced neurotoxicity in cholinergic cells differentiated from bone marrow-derived mesenchymal stem cells. <i>Toxicology and Industrial Health</i> , 2022, 38, 655-664.	0.6	2
1324	Triple negative breast cancer-derived small extracellular vesicles as modulator of biomechanics in target cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 44, 102582.	1.7	5
1326	Cancer cells corrupt normal epithelial cells through miR-let-7c-rich small extracellular vesicle-mediated downregulation of p53/PTEN. <i>International Journal of Oral Science</i> , 2022, 14, .	3.6	4
1327	Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF- α monoclonal antibody. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121969.	2.6	10
1328	HMGA2-Snai2 axis regulates tumorigenicity and stemness of head and neck squamous cell carcinoma. <i>Experimental Cell Research</i> , 2022, 418, 113271.	1.2	11
1329	A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114564.	2.6	14
1330	PI3K γ activity controls plasticity and discriminates between EMT and stemness based on distinct TGF β signaling. <i>Communications Biology</i> , 2022, 5, .	2.0	3
1331	Activation of the integrated stress response is a vulnerability for multidrug-resistant FBXW7-deficient cells. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	12
1332	Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma. <i>WIREs Mechanisms of Disease</i> , 2022, 14, .	1.5	1
1333	PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1334	Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1335	S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3-mediated programmed death ligand 1 expression in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	7
1336	Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
1337	Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer. <i>Current Pharmaceutical Design</i> , 2022, 28, 2298-2311.	0.9	7
1338	FZD7 accelerates hepatic metastases in pancreatic cancer by strengthening EMT and stemness associated with TGF- β 2/SMAD3 signaling. <i>Molecular Medicine</i> , 2022, 28, .	1.9	16
1339	Connexin32 regulates expansion of liver cancer stem cells via the PI3K/Akt signaling pathway. <i>Oncology Reports</i> , 2022, 48, .	1.2	1
1340	Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
1341	Stem Cell Models for Breast and Colon Cancer: Experimental Approach for Drug Discovery. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9223.	1.8	3
1342	Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy. <i>Acta Biomaterialia</i> , 2022, 152, 380-392.	4.1	9
1343	Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance. , 2022, 10, e004832.		17
1344	DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1236-1249.	3.2	8
1345	Zeb1 sustains hematopoietic stem cell functions by suppressing mitofusin-2-mediated mitochondrial fusion. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	3
1346	Acridine Derivative for Biomedical Application: Current State of the Art. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 11415-11432.	2.9	12
1347	The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 871-898.	2.7	8
1348	A promising antitumor method: Targeting CSC with immune cells modified with CAR. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1349	Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate. <i>Cancers</i> , 2022, 14, 3903.	1.7	4
1350	NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1
1351	A Hybrid Epithelial to Mesenchymal Transition in Ex Vivo Cutaneous Squamous Cell Carcinoma Tissues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9183.	1.8	1
1352	Minimally invasive detection of cancer using metabolic changes in tumor-associated natural killer cells with Oncoimmune probes. <i>Nature Communications</i> , 2022, 13, .	5.8	7
1353	Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	17
1354	ICAM1 promotes bone metastasis via integrin-mediated TGF- β 2/EMT signaling in triple-negative breast cancer. <i>Cancer Science</i> , 2022, 113, 3751-3765.	1.7	10

#	ARTICLE	IF	CITATIONS
1355	Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	55
1356	Fate decisions of breast cancer stem cells in cancer progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1357	The Role of PTEN in Epithelialâ€“Mesenchymal Transition. <i>Cancers</i> , 2022, 14, 3786.	1.7	8
1358	Potential Role of Cancer Stem Cells in Glioblastoma: A Therapeutic Aspect. , 0, , .		0
1359	An anti-alcoholism drug, disulfiram and copper complex improves radio-resistance of tumor-initiating cells in esophageal squamous cell carcinoma. <i>Esophagus</i> , 2023, 20, 134-142.	1.0	1
1360	Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2023, 41, 472-478.	0.8	17
1361	Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. <i>Pharmacological Research</i> , 2022, 184, 106456.	3.1	13
1362	Long-term resistance to 5-fluorouracil promotes epithelialâ€“mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells. <i>European Journal of Pharmacology</i> , 2022, 933, 175253.	1.7	5
1363	An investigation of bacteriocin nisin anti-cancer effects and FZD7 protein interactions in liver cancer cells. <i>Chemico-Biological Interactions</i> , 2022, 366, 110152.	1.7	7
1364	Echinacoside (ECH) suppresses proliferation, migration, and invasion of human glioblastoma cells by inhibiting Skp2-triggered epithelial-mesenchymal transition (EMT). <i>European Journal of Pharmacology</i> , 2022, 932, 175176.	1.7	5
1365	Mesenchymal stem/stromal cells in breast cancer development and management. <i>Seminars in Cancer Biology</i> , 2022, 86, 81-92.	4.3	13
1366	Pathogenesis of periodontitis â€“ A potential role for epithelial-mesenchymal transition. <i>Japanese Dental Science Review</i> , 2022, 58, 268-278.	2.0	15
1367	Silencing of RNA binding protein, ZFP36L1, promotes epithelial-mesenchymal transition in liver cancer cells by regulating transcription factor ZEB2. <i>Cellular Signalling</i> , 2022, 100, 110462.	1.7	4
1368	Cell adhesion molecules E-cadherin and CADM1 are differently expressed in canine inflammatory mammary cancer. <i>Research in Veterinary Science</i> , 2022, 152, 307-313.	0.9	3
1369	<i>Artemisia argyi</i> extract induces apoptosis in human gemcitabine-resistant lung cancer cells via the PI3K/MAPK signaling pathway. <i>Journal of Ethnopharmacology</i> , 2022, 299, 115658.	2.0	16
1370	SNHG16 upregulation-induced positive feedback loop with YAP1/TEAD1 complex in Colorectal Cancer cell lines facilitates liver metastasis of colorectal cancer by modulating CTCs epithelial-mesenchymal transition. <i>International Journal of Biological Sciences</i> , 2022, 18, 5291-5308.	2.6	8
1371	The Mechanism by Which SIRT1 Regulates Autophagy and EMT in Drug-Resistant Oesophageal Cancer Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1372	SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway. <i>International Journal of Biological Sciences</i> , 2022, 18, 5241-5259.	2.6	8

#	ARTICLE	IF	CITATIONS
1373	Subpopulation cooperation renders drug resistance of hepatobiliary tumor organoids. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 422-424.	0.7	0
1374	Reactive Oxygen Species and Cancer Stem Cells: Molecular Interactions and Their Implications in Cancer. , 2022, , 2227-2268.		0
1375	Reactive Oxygen Species and Cancer Stem Cells: Molecular Interactions and Their Implications in Cancer. , 2022, , 1-42.		0
1376	Drawbacks of Bench to Bed Translation of Nanomedicines for Cancer Treatment. Emergence, Complexity and Computation, 2022, , 253-267.	0.2	0
1377	Quantifying epithelial-mesenchymal heterogeneity and EMT scoring in tumor samples via tyramide signal amplification (TSA). Methods in Cell Biology, 2022, , 149-161.	0.5	2
1378	A Metabolic Plasticity-Based Signature for Molecular Classification and Prognosis of Lower-Grade Glioma. Brain Sciences, 2022, 12, 1138.	1.1	4
1379	Epigenetic tumor heterogeneity in the era of single-cell profiling with nanopore sequencing. Clinical Epigenetics, 2022, 14, .	1.8	9
1380	Low mitochondrial DNA copy number induces chemotherapy resistance via epithelial-mesenchymal transition by DNA methylation in esophageal squamous cancer cells. Journal of Translational Medicine, 2022, 20, .	1.8	3
1381	Exosomal lncRNA PCAT1 Promotes Tumor Circulating Cell-Mediated Colorectal Cancer Liver Metastasis by Regulating the Activity of the miR-329-3p/Netrin-1-CD146 Complex. Journal of Immunology Research, 2022, 2022, 1-13.	0.9	17
1382	Analysis of Dormancy-Associated Transcriptional Networks Reveals a Shared Quiescence Signature in Lung and Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 9869.	1.8	9
1383	Peroxidase is a novel potential marker in glioblastoma through bioinformatics method and experimental validation. Frontiers in Genetics, 0, 13, .	1.1	0
1385	Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS ONE, 2022, 17, e0274607.	1.1	20
1386	Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Molecular and Cellular Proteomics, 2022, 21, 100409.	2.5	6
1388	Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	7
1389	Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. Analytical Chemistry, 0, , .	3.2	0
1390	Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer. Cancers, 2022, 14, 4423.	1.7	6
1392	DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway. Molecules, 2022, 27, 6146.	1.7	2
1394	The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	31

#	ARTICLE	IF	CITATIONS
1395	Identification of Prognostic Markers and Potential Therapeutic Targets in Gastric Adenocarcinoma by Machine Learning Based on mRNAsi Index. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	3
1396	A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	11
1397	Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	18
1398	Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer. <i>Biomaterials</i> , 2022, 290, 121827.	5.7	9
1399	Conjugated Linoleic Acid Treatment Attenuates Cancerous features in Hepatocellular Carcinoma Cells. <i>Stem Cells International</i> , 2022, 2022, 1-14.	1.2	4
1400	Evidence that cervical cancer cells cultured as tumorspheres maintain high CD73 expression and increase their protumor characteristics through TGF β 2 production. <i>Cell Biochemistry and Function</i> , 2022, 40, 760-772.	1.4	7
1402	Stem Cells: Therapeutic Implications in Chemotherapy and Radiotherapy Resistance in Cancer Therapy. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 750-765.	0.6	3
1403	TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1
1405	A systems biology investigation of curcumin potency against TGF- β 2-induced EMT signaling in lung cancer. <i>3 Biotech</i> , 2022, 12, .	1.1	2
1406	Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer. <i>Gene</i> , 2023, 850, 146930.	1.0	1
1407	Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial-mesenchymal transition in drug-resistant lung cancer. <i>Pharmacological Research</i> , 2022, 185, 106490.	3.1	10
1408	ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. <i>Theranostics</i> , 2022, 12, 7051-7066.	4.6	8
1409	Biosynthetic Luminescent Ag Nanoparticles in Functionalization for Breast Cancer Therapy. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 1553-1561.	0.5	0
1410	Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1411	MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	13
1412	Diethyldithiocarbamate copper nanoparticle overcomes resistance in cancer therapy without inhibiting P-glycoprotein. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 47, 102620.	1.7	9
1413	Early myeloid-derived suppressor cells accelerate epithelial-mesenchymal transition by downregulating ARID1A in luminal A breast cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1414	Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription. <i>Molecular Cancer Research</i> , 2023, 21, 115-126.	1.5	1

#	ARTICLE	IF	CITATIONS
1415	CD133 ⁺ Src ⁺ TAZ signaling stimulates ductal fibrosis following DDC diet ⁺ induced liver injury. <i>Journal of Cellular Physiology</i> , 2022, 237, 4504-4516.	2.0	3
1416	Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m6A demethylation. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	17
1418	A Novel Detection Method of Breast Cancer through a Simple Panel of Biomarkers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11983.	1.8	0
1419	MiR-330-5p and miR-1270 target essential components of RNA polymerase I transcription and exhibit a novel tumor suppressor role in lung adenocarcinoma. <i>Cancer Gene Therapy</i> , 2023, 30, 288-301.	2.2	1
1420	Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer. <i>Oncogene</i> , 2022, 41, 5176-5185.	2.6	4
1421	CDX2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in Colorectal Cancer. <i>Disease Markers</i> , 2022, 2022, 1-13.	0.6	4
1422	ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1423	Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1424	EBV promotes vascular mimicry of dormant cancer cells by potentiating stemness and EMT. <i>Experimental Cell Research</i> , 2022, 421, 113403.	1.2	5
1425	Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. <i>Science Advances</i> , 2022, 8, .	4.7	3
1426	<sc>spliceJAC</sc> : transition genes and state ⁺ specific gene regulation from single ⁺ cell transcriptome data. <i>Molecular Systems Biology</i> , 2022, 18, .	3.2	14
1427	CD166-specific CAR-T cells potently target colorectal cancer cells. <i>Translational Oncology</i> , 2023, 27, 101575.	1.7	4
1428	CENP-A: A Histone H3 Variant with Key Roles in Centromere Architecture in Healthy and Diseased States. <i>Results and Problems in Cell Differentiation</i> , 2022, , 221-261.	0.2	1
1429	Targeting PI3K/Akt signaling in prostate cancer therapy. <i>Journal of Cell Communication and Signaling</i> , 2023, 17, 423-443.	1.8	15
1430	Weaponizing natural killer cells for solid cancer immunotherapy. <i>Trends in Cancer</i> , 2023, 9, 111-121.	3.8	5
1431	Roles of m ⁶ A modification in oral cancer (Review). <i>International Journal of Oncology</i> , 2022, 62, .	1.4	2
1432	Cellular Prion Protein Role in Cancer Biology: Is It A Potential Therapeutic Target?. <i>Biomedicines</i> , 2022, 10, 2833.	1.4	5
1433	Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties. <i>Pharmaceuticals</i> , 2022, 15, 1369.	1.7	2

#	ARTICLE	IF	CITATIONS
1434	The TGF β ^{2/3} /Smad signaling pathway is involved in Musashi2 α -induced invasion and metastasis of colorectal cancer. <i>Molecular Carcinogenesis</i> , 2023, 62, 261-276.	1.3	1
1435	Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14058.	1.8	2
1437	Presence of cells in the polyaneploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer. <i>Prostate</i> , 2023, 83, 277-285.	1.2	4
1438	Potential Role of the Circadian Clock in the Regulation of Cancer Stem Cells and Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14181.	1.8	4
1439	Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1262-1273.	5.7	8
1440	Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer. <i>Seminars in Cancer Biology</i> , 2022, 87, 48-83.	4.3	10
1441	The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113959.	2.5	4
1442	Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy. <i>Seminars in Cancer Biology</i> , 2022, 87, 84-97.	4.3	13
1443	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. <i>Cancers</i> , 2022, 14, 5668.	1.7	3
1444	Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment. <i>Drug Resistance Updates</i> , 2023, 66, 100904.	6.5	20
1445	CD44 and CD133 aptamer directed nanocarriers for cancer stem cells targeting. <i>European Polymer Journal</i> , 2023, 183, 111770.	2.6	11
1446	Tumour cell heterogeneity in triple-negative breast cancer cells affects response to cisplatin, but not doxorubicin. <i>Journal of Inorganic Biochemistry</i> , 2023, 239, 112082.	1.5	4
1447	The roles of Linc-ROR in the regulation of cancer stem cells. <i>Translational Oncology</i> , 2023, 28, 101602.	1.7	0
1448	Subcellular elements responsive to the biomechanical activity of triple-negative breast cancer-derived small extracellular vesicles. <i>Biomolecular Concepts</i> , 2022, 13, 322-333.	1.0	2
1449	Exosome-based cancer stem cell communication: Implication for detecting and eliminating cancer stem cells. , 2022, 1, .		1
1450	Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP β . <i>Small</i> , 2023, 19, .	5.2	6
1451	MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going. <i>Cancers</i> , 2022, 14, 5731.	1.7	1
1452	Effect of Cepharanthine on the Stemness of Lung Squamous Cell Carcinoma Based on Network Pharmacology and Bioinformatics. <i>BioMed Research International</i> , 2022, 2022, 1-13.	0.9	0

#	ARTICLE	IF	CITATIONS
1453	Carbon nanoparticles induce DNA repair and PARP inhibitor resistance associated with nanozyme activity in cancer cells. <i>Cancer Nanotechnology</i> , 2022, 13, .	1.9	7
1454	RASSF1A inhibits epithelialâ€mesenchymal transition of gastric cancer cells by downregulating Pâ€JNK. <i>Cell Biology International</i> , 0, , .	1.4	0
1455	A role for EMT in CD73 regulation in breast cancer. <i>Oncolimmunology</i> , 2022, 11, .	2.1	0
1456	Cancer Stem Cellsâ€The Insight into Non-Coding RNAs. <i>Cells</i> , 2022, 11, 3699.	1.8	2
1458	Mechanisms of colorectal liver metastasis development. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	7
1459	The role of Hedgehog and Notch signaling pathway in cancer. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	11
1460	AKAP8L enhances the stemness and chemoresistance of gastric cancer cells by stabilizing SCD1 mRNA. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	4
1461	Prognostic value of TMEM59L and its genomic and immunological characteristics in cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1462	Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. <i>Cancers</i> , 2022, 14, 6101.	1.7	4
1463	COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	0
1464	Mechanisms of radioresistance and the underlying signaling pathways in colorectal cancer cells. <i>Journal of Cellular Biochemistry</i> , 2023, 124, 31-45.	1.2	2
1465	TWIST1 activates cancer stem cell marker genes to promote epithelial-mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
1466	Î”Np63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells. <i>Developmental Cell</i> , 2022, 57, 2714-2730.e8.	3.1	10
1467	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
1468	Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies. <i>ELife</i> , 0, 11, .	2.8	4
1469	The Metastatic Process through the Eyes of Epigenetic Regulation: A Promising Horizon for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15446.	1.8	0
1471	Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1472	SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production. <i>Aging</i> , 2022, 14, 9877-9889.	1.4	2

#	ARTICLE	IF	CITATIONS
1473	Loss of Dok-3 in Non-tumor Cells Induces Malignant Transformation of Benign Epithelial Tumor Cells of the Intestine. <i>Cancer Research Communications</i> , 2022, 2, 1590-1600.	0.7	0
1475	Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC. <i>3 Biotech</i> , 2023, 13, .	1.1	1
1476	ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer. <i>Clinical and Translational Oncology</i> , 2023, 25, 1425-1435.	1.2	6
1477	TRIM44 regulates tumor immunity in gastric cancer through LOXL2-dependent extracellular matrix remodeling. <i>Cellular Oncology (Dordrecht)</i> , 0, , .	2.1	3
1478	CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer. , 2023, 40, .		2
1479	Heterogeneous expression and role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in small cell lung cancer. <i>Human Cell</i> , 0, , .	1.2	0
1480	TWIST1 Plays Role in Expression of Stemness State Markers in ESCC. <i>Genes</i> , 2022, 13, 2369.	1.0	1
1481	The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. <i>Cell Reports</i> , 2022, 41, 111819.	2.9	4
1482	Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells. <i>Cancers</i> , 2022, 14, 6214.	1.7	2
1483	The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. <i>Cancers</i> , 2023, 15, 62.	1.7	17
1485	ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1486	ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment. <i>Oncology Reports</i> , 2022, 49, .	1.2	0
1487	Alterations of Cytoskeleton Networks in Cell Fate Determination and Cancer Development. <i>Biomolecules</i> , 2022, 12, 1862.	1.8	3
1488	Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2023, 10, 1-8.	0.2	0
1489	Evaluation of the proteomic landscape of HPV E7-induced alterations in human keratinocytes reveal therapeutically relevant pathways for cervical cancer. <i>Molecular Medicine Reports</i> , 2023, 27, .	1.1	0
1490	Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer. <i>Cancer Research</i> , 2023, 83, 735-752.	0.4	11
1491	Exploring the role of tumor stemness and the potential of stemness-related risk model in the prognosis of intrahepatic cholangiocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1492	Epithelial-to-Mesenchymal Transition and Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 1-49.	0.8	0

#	ARTICLE	IF	CITATIONS
1494	Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer. <i>Bioengineering</i> , 2023, 10, 91.	1.6	0
1495	IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?. <i>Biomedicines</i> , 2023, 11, 229.	1.4	10
1497	MAD2L1 is transcriptionally regulated by TEAD4 and promotes cell proliferation and migration in colorectal cancer. <i>Cancer Gene Therapy</i> , 2023, 30, 727-737.	2.2	2
1498	RNA methylation and cellular response to oxidative stress-promoting anticancer agents. <i>Cell Cycle</i> , 2023, 22, 870-905.	1.3	7
1499	An immune and epithelial-mesenchymal transition-related risk model and immunotherapy strategy for grade II and III gliomas. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
1500	Treatment dependent impact of plasma-derived exosomes from head and neck cancer patients on the epithelial-to-mesenchymal transition. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1501	PTBP1 drives c-Myc-dependent gastric cancer progression and stemness. <i>British Journal of Cancer</i> , 2023, 128, 1005-1018.	2.9	5
1502	Nintedanib- α 6 Integrin Ligand Conjugates Reduce TGF β -Induced EMT in Human Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1475.	1.8	0
1504	Total flavonoids of Litchi seed attenuate stem cell-like properties in breast cancer by regulating Notch3 signaling pathway. <i>Journal of Ethnopharmacology</i> , 2023, 305, 116133.	2.0	2
1505	CANCER STEM CELLS: THE GREATEST MENACE IN CONQUERING CANCER MANAGEMENT. <i>Towards Excellence</i> , 0, , 954-975.	0.0	1
1506	Annexin A1 affects tumor metastasis through epithelial-mesenchymal transition: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 4416-4433.	0.4	3
1507	Linc-ROR drive adriamycin resistance by targeting AP-2/Wnt/ β -catenin axis in hepatocellular carcinoma. <i>Cell Biology and Toxicology</i> , 0, , .	2.4	1
1508	Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	5
1509	miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	3
1510	Cancer-Associated Fibroblasts Promote Radioresistance of Breast Cancer Cells via the HGF/c-Met Signaling Pathway. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 640-654.	0.4	7
1511	An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. <i>Veterinary Sciences</i> , 2023, 10, 19.	0.6	4
1512	The miRNA125a-5p and miRNA125b-1-5p cluster induces cell invasion by down-regulating DDB2-reduced epithelial-to-mesenchymal transition (EMT) in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 3112-3122.	0.6	3
1513	circRNAs in drug resistance of breast cancer. <i>Oncology Research</i> , 2022, 30, 157-172.	0.6	2

#	ARTICLE	IF	CITATIONS
1514	Mechanisms of multidrug resistance in cancer. , 2023, , 51-83.		0
1515	Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs. , 2023, , 55-70.		0
1516	Cancer cell-derived novel periostin isoform promotes invasion in head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 8510-8525.	1.3	4
1517	A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States. <i>Cancer Research</i> , 2023, 83, 956-970.	0.4	1
1518	The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311552.	0.8	0
1519	Editorial: Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	7
1520	Tumor immunology. , 2023, , 245-452.		0
1522	RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer. <i>Cells</i> , 2023, 12, 444.	1.8	9
1523	Pan-cancer analysis of the deoxyribonuclease gene family. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	0
1524	Theranostics application of tumor-initiating cell probe TiY in non-small cell lung cancer. <i>Theranostics</i> , 2023, 13, 1370-1380.	4.6	0
1525	Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. <i>Nature Communications</i> , 2023, 14, .	5.8	14
1527	RHOJ controls EMT-associated resistance to chemotherapy. <i>Nature</i> , 2023, 616, 168-175.	13.7	38
1528	A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7238.	1.8	2
1529	Increased soluble E-cadherin of spheroid formation supplemented with fetal bovine serum in colorectal cancer cells. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
1530	Non-coding RNAs in radiotherapy resistance: Roles and therapeutic implications in gastrointestinal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114485.	2.5	0
1531	Slow skeletal muscle troponin T acts as a potential prognostic biomarker and therapeutic target for hepatocellular carcinoma. <i>Gene</i> , 2023, 865, 147331.	1.0	1
1532	Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. <i>Advanced Drug Delivery Reviews</i> , 2023, 196, 114773.	6.6	26
1533	Low-dose BPA and its substitute BPS promote ovarian cancer cell stemness via a non-canonical PINK1/p53 mitophagic signaling. <i>Journal of Hazardous Materials</i> , 2023, 452, 131288.	6.5	7

#	ARTICLE	IF	CITATIONS
1534	NOTCH pathway inactivation reprograms stem-like oral cancer cells to JAK-STAT dependent state and provides the opportunity of synthetic lethality. <i>Translational Oncology</i> , 2023, 32, 101669.	1.7	2
1536	TM4SF1 upregulates MYH9 to activate the NOTCH pathway to promote cancer stemness and lenvatinib resistance in HCC. <i>Biology Direct</i> , 2023, 18, .	1.9	5
1537	A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer. <i>Seminars in Cancer Biology</i> , 2023, 90, 15-28.	4.3	18
1538	Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103920.	2.0	18
1539	Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer. <i>Journal of Controlled Release</i> , 2023, 354, 784-793.	4.8	4
1540	Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. <i>Molecular Cell</i> , 2023, 83, 803-818.e8.	4.5	6
1541	Camptothecin improves sorafenib sensitivity by inhibiting Nrf2â€‘ARE pathway in hepatocellular carcinoma. <i>Oncology Reports</i> , 2023, 49, .	1.2	2
1542	Nearâ€‘Death Cells Cause Chemotherapyâ€‘Induced Metastasis via ATF4â€‘Mediated NFâ€‘ κ B Signaling Activation. <i>Advanced Science</i> , 2023, 10, .	5.6	3
1543	Epithelial-mesenchymal transition as a potential route for DAPT resistance in breast cancer cells. <i>Biyokimya Dergisi</i> , 2023, 48, 88-95.	0.1	0
1544	Cutting Off H ⁺ Leaks on the Inner Mitochondrial Membrane: A Proton Modulation Approach to Selectively Eradicate Cancer Stem Cells. <i>Journal of the American Chemical Society</i> , 2023, 145, 4647-4658.	6.6	3
1545	Identification of stemness subtypes and features to improve endometrial cancer treatment using machine learning. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2023, 51, 57-73.	1.9	1
1546	The essential role of forkhead box P4 (FOXP4) in thyroid cancer: a study related to The Cancer Genome Atlas and experimental data. <i>Endocrine Connections</i> , 2023, 12, .	0.8	0
1548	LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. <i>Cancer Gene Therapy</i> , 2023, 30, 855-865.	2.2	6
1549	How cells sense and integrate information from different sources. <i>WIREs Mechanisms of Disease</i> , 2023, 15, .	1.5	2
1550	Integrin α 2 β 3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1216.	1.7	4
1551	Luteolin directly binds to KDM4C and attenuates ovarian cancer stemness via epigenetic suppression of PPP2CA/YAP axis. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114350.	2.5	5
1552	Heterogeneity and plasticity of epithelialâ€‘mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms. <i>Cell Proliferation</i> , 2023, 56, .	2.4	22
1553	Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. <i>MedComm</i> , 2023, 4, .	3.1	9

#	ARTICLE	IF	CITATIONS
1554	Retinoblastoma-Binding Protein 5 Regulates H3K4 Methylation Modification to Inhibit the Proliferation of Melanoma Cells by Inactivating the Wnt/ β -Catenin and Epithelial-Mesenchymal Transition Pathways. <i>Journal of Oncology</i> , 2023, 2023, 1-19.	0.6	2
1555	Lipogenesis promotes mitochondrial fusion and maintains cancer stemness in human NSCLC. <i>JCI Insight</i> , 2023, 8, .	2.3	2
1556	Redox signaling in drug-tolerant persister cells as an emerging therapeutic target. <i>EBioMedicine</i> , 2023, 89, 104483.	2.7	15
1557	JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	24
1558	S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. <i>Cell Death and Differentiation</i> , 2023, 30, 1155-1165.	5.0	4
1560	Invasion and Metastasis. , 2023, , 205-234.		0
1561	<sc>MicroRNA</sc> 483p overexpression unleashes invasive growth of metastatic colorectal cancer via <sc><i>NDRG1</i></sc> downregulation and ensuing activation of the <sc>ERBB3</sc>/<sc>AKT</sc> axis. <i>Molecular Oncology</i> , 2023, 17, 1280-1301.	2.1	1
1562	An implantable composite scaffold for amplified chemodynamic therapy and tissue regeneration. <i>Journal of Materials Chemistry B</i> , 2023, 11, 3151-3163.	2.9	0
1563	EpithelialߝMesenchymal Transition Expression Profile Stratifies Human Glioma into Two Distinct Tumor-Immune Subtypes. <i>Brain Sciences</i> , 2023, 13, 447.	1.1	1
1564	Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4997.	1.8	3
1566	Intercellular hif1ࢣ reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	3
1567	Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
1569	Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2172-2187.	1.9	1
1570	Current perspectives of mitochondria-targeted antioxidants in cancer prevention and treatment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	6
1571	Construction of Metastasis-Specific Regulation Network in Ovarian Cancer Based on Prognostic Stemness-Related Signatures. <i>Reproductive Sciences</i> , 0, , .	1.1	0
1572	An orthogonally activatable CRISPR-Cas13d nanoprodug to reverse chemoresistance for enhanced chemo-photodynamic therapy. <i>Chemical Science</i> , 2023, 14, 4102-4113.	3.7	6
1573	Effect of ZEB1 Associated with microRNAs on Tumor Stem Cells in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5916.	1.8	2
1574	Modulation of redox homeostasis: A strategy to overcome cancer drug resistance. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4

#	ARTICLE	IF	CITATIONS
1575	Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. <i>Advances in Cancer Research</i> , 2023, , .	1.9	0
1576	Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF- β ² growth-suppressive signaling in BCR-ABL1-positive leukemia. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
1577	EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	6
1578	Bufalin-loaded vitamin E succinate-grafted chitosan oligosaccharide/RGD-conjugated TPGS mixed micelles inhibit intraperitoneal metastasis of ovarian cancer. <i>Cancer Nanotechnology</i> , 2023, 14, .	1.9	1
1579	Cutting the root: the next generation of T cells engagers against cancer stem cells to overcome drug resistance in triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2023, 20, 169-173.	1.4	0
1580	LncRNA LITATS1 suppresses TGF β ² -induced EMT and cancer cell plasticity by potentiating T β RI degradation. <i>EMBO Journal</i> , 2023, 42, .	3.5	14
1581	Comparative analysis of clinicopathological characteristics of central necrotizing breast cancer and basal cell-like breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1582	TMPRSS4, a type II transmembrane serine protease, as a potential therapeutic target in cancer. <i>Experimental and Molecular Medicine</i> , 2023, 55, 716-724.	3.2	1
1583	Competitive Effect of Overexpressed C-terminal of Snail-1 (CSnail) in Control of the Growth and Metastasis of Melanoma Cells. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2024, 19, 342-353.	0.8	0
1584	A novel computational predictive biological approach distinguishes Integrin β ¹ as a salient biomarker for breast cancer chemoresistance. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166702.	1.8	0
1585	Selective ablation of TRA-1-60 ⁺ pluripotent stem cells suppresses tumor growth of prostate cancer. <i>Theranostics</i> , 2023, 13, 2057-2071.	4.6	0
1586	Integrated analysis based on vesicle trafficking-related genes identifying CNIH4 as a novel therapeutic target for glioma. <i>Cancer Medicine</i> , 0, , .	1.3	1
1587	Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling. <i>Breast Cancer Research</i> , 2023, 25, .	2.2	4
1588	Epigenetic regulation of stem cells in lung cancer oncogenesis and therapy resistance. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	4
1589	High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1590	Metastatic niches in patients with high-grade neuroendocrine tumours: Apparent findings of matched triple-positive radiolabelled molecular probes by nuclear medicine sequence imaging. <i>Advances in Cancer Biology Metastasis</i> , 2023, , 100100.	1.1	0
1645	Targeting Immune Determinants of Creating Tumor Heterogeneity in Lung Cancer. , 2023, , .		0
1656	Reactive Oxygen Species and Cancer Stem Cells: Molecular Interactions and Their Implications in Cancer. , 2023, , 1-42.		0

#	ARTICLE	IF	CITATIONS
1672	Breast cancers as ecosystems: a metabolic perspective. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	2
1677	Evolutionary determinants of curability in cancer. Nature Ecology and Evolution, 0, , .	3.4	1
1711	Cancer Stem Cells (CSCs) in Tumor Ecosystem. , 2023, , 371-387.		0
1717	Amino Acids Transport as an Index of Cancer Stem Cells Dysregulation. , 2023, , 1-24.		0
1745	Cancer stem cellâ€derived exosomes: what is known to date. , 2024, , 591-607.		0
1750	EMT-induced immune evasion: connecting the dots from mechanisms to therapy. Clinical and Experimental Medicine, 2023, 23, 4265-4287.	1.9	2
1751	Photodynamic therapy in cancer stem cells â€” state of the art. Lasers in Medical Science, 2023, 38, .	1.0	1
1754	Eph receptors and ephrins in cancer progression. Nature Reviews Cancer, 2024, 24, 5-27.	12.8	4
1759	Understanding vitamin D from mouse knockout models. , 2024, , 609-632.		0
1760	Colorectal cancer stem cells: overview and potential targeted therapy. , 2024, , 185-205.		1
1786	Mesenchymal Stem Cells, Cancer Stem Cells (CSCs), and Circulating Tumor Cells (CTCs): Roles and Combinations in Tumor Growth and Dissemination. , 2023, , 1-23.		0
1795	The APE1/REF-1 and the hallmarks of cancer. Molecular Biology Reports, 2024, 51, .	1.0	1
1799	Deciphering cellular plasticity in pancreatic cancer for effective treatments. Cancer and Metastasis Reviews, 2024, 43, 393-408.	2.7	0
1807	From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy. Histochemistry and Cell Biology, 2024, 161, 299-323.	0.8	1
1814	The role of stromal cells in epithelialâ€mesenchymal plasticity and its therapeutic potential. Discover Oncology, 2024, 15, .	0.8	0
1818	Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer and Metastasis Reviews, 2024, 43, 197-228.	2.7	0
1837	Tumor-Microenvironment-on-Chip Platform for Assessing Drug Response in 3D Dynamic Culture. Methods in Molecular Biology, 2024, , 265-278.	0.4	0
1848	Invasion und Metastasierung. , 2024, , 239-272.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------